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ABSTRACT 
Angela Odiachi: The Impact of Disclosure on Health Outcomes in HIV-Infected Nigerian Children 
(Under the direction of Harsha Thirumurthy) 
 
AIM: The study aimed to determine the prevalence, age and main agent of disclosure among Nigerian 
children on antiretroviral treatment. The study also sought to elicit barriers to, and facilitators of 
disclosure, and the context and process of disclosure. METHODS: In this cross-sectional, facility-based 
study, a semi-structured questionnaire was administered to 110 parents/caregivers of children ≥ 6 
years, to determine child’s disclosure status. This was followed by a more detailed interview with 15 
parent/caregivers of disclosed children. CD4, viral load, opportunistic infections and adherence 
information were also extracted from medical records for all 110 children. RESULTS: The mean age (SD) 
of the children in the study was 10.15 (2.97) years, with a median (range) of 9.50 (6 – 18) years. 
According to parents/caregivers’ accounts 34 (30.9%) children knew they were living with HIV, while 74 
(67.3%) did not know. Mean age (SD) at disclosure was 10.47 (2.62) years, with a median (range) of 
10.00 (6 - 17) years. Most of the children (79.4%) were disclosed at home by their parent(s)/caregiver. 
The rest were disclosed at the hospital: five were disclosed by a health care provider, while two were 
accidental disclosure. The most common reasons for disclosure were related to adherence issues – 
either to help prepare the children to take their medicines or that the child had refused to take his/her 
medicines (39.4%). This was followed by the child asking a lot of questions related to his/her health, 
frequent visits to the hospital, or why s/he was taking a lot of medicines even though s/he did not feel ill 
(27.3%). Most parents/ caregivers did not disclose because the child was considered too young (84.0%) 
or will not be able to keep their HIV status a secret (10.7%). Disclosure was mostly unplanned and a one-
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off event. Children’s reaction to disclosure ranged from no reaction to shock and crying. Multivariate 
logistic regression showed that only child’s age was a statistically significant predictor of status 
disclosure (OR 1.69, p=0.002; 95% CI 1.21 – 2.34). The study did not show any association between 
disclosure and other child and parent/caregiver characteristics. There was no association between 
disclosure and self-reported adherence (p=0.615).  
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CHAPTER 1 
INTRODUCTION 
Ninety percent of the 2.5 million children infected with HIV live in Sub-Saharan Africa (SSA) [1]. Despite 
significant increases in access to antiretroviral drugs (ARV) Prevention of Mother-to-Child (PMTCT) 
programs in resource-limited countries are fraught with major challenges and coverage is not complete.   
Consequently, many children continue to be infected perinatally with HIV.  However, as a result of ARV 
access, these children are living longer [2]. Thus, a generation of children living with HIV (CLHIV) is 
coming of age. As these children approach adolescence, many of them have not been disclosed to, i.e. 
they have not been told they are living with HIV. The term disclosure, in this context, refers to informing 
children that they have HIV. World Health Organisation Guideline on HIV Counselling for Children up to 
12 years of Age recommends that children of school age (6-12 years) be told they have HIV [3].  The 
American Academy of Pediatrics also recommends HIV status disclosure to school aged children [4]. 
Disclosure prevalence from four studies in developing countries ranged from 29% to 62 % [2]. 
Vaz et al. [2] reported only 3% pediatric disclosure in their study in the Democratic Republic of Congo, 
while Vreeman et al. [5]  also reported almost 100% non-disclosure. More recent studies on SSA have 
similarly reported low disclosure rates - 13.5% (Nigeria), 21% (Ghana), 17.4% and 39.5% (Ethiopia), 19% 
and 26% (Kenya), and 32.6% (Cote d’Ivoire) [6-12]. Factors that influence pediatric disclosure include 
child’s age and cognitive development, concerns around antiretroviral treatment (ART) adherence, 
imminent onset of sexual activity, and the need to protect others from infection. Benefits of pediatric 
disclosure include improved adherence to ART, and psychosocial well-being and mental health. Despite 
these benefits of disclosure, nondisclosure remains high because disclosure carries with it a negative 
1 
2 
 
 
exposure due to the association of HIV positive status and sex (promiscuity). Disclosure of HIV status to 
children living with HIV, or to partners, remains ‘navigation in a moral field’ [13]. Therefore to protect 
the family name and one’s reputation, and avoid rejection and discrimination, many choose not to 
disclose HIV status to children.  
Literature on disclosure suggests that when disclosure does happen, it is not done in a 
systematic way [2]. The process remains largely context dependent. It is also not clear whether there are 
policies and guidelines on pediatric disclosure in many countries. Yet, disclosure could be a potent force 
in the prevention and control of HIV infection to those not infected, and for those who are already 
infected it provides an opportunity for improved quality of life for the HIV infected and their families, 
and slowing of disease progression. 
This study, therefore, aimed to explore the association between pediatric disclosure i.e. 
disclosure of child’s seropositive HIV status, and health outcomes among children living with HIV in 
Nigeria: Is there any correlation between HIV disclosure and improved or worsened health – physical, 
psychological, or other dimensions of health? The study also aimed to assess the prevalence, patterns 
and predictors of HIV status disclosure to children. The study also looked at non-disclosure to determine 
if there were any relevant ethical issues to consider in pediatric disclosure, and how these would be 
applicable to the SSA context; and how disclosure policies and guidelines would facilitate or support HIV 
control measures.  
While the literature review looked at pediatric HIV disclosure in all contexts, particular interest 
was on SSA, since most CLHIV reside in this part of the world. As much as possible, the literature review 
also attempted to tease out any regional differences, if any, on health outcomes and HIV disclosure. 
Nigeria 
Nigeria is the most populous country in Africa with a 2013 projected population of over 170 million 
people.  Situated in West Africa, Nigeria is bordered by Niger Republic, Chad, Benin Republic, Cameroun, 
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and the Atlantic Ocean. Its 36 states and Federal Capital Territory Abuja are further divided into 774 
local government areas in six geopolitical zones (South east, South south, South west, North central, 
North east and North west). The main religions in the country are Christianity, Islam and Traditional 
religions.  
HIV in Nigeria 
With an estimated 3.4 million people (including 430,000 children under 15 years) living with HIV [1], 
Nigeria has the second highest number of persons living with HIV in the world, after South Africa.  The 
first HIV case in Nigeria was reported in 1986. Since then the HIV prevalence rate has changed from 
1.8% in 1991 to 5.8% in 2001, then 4.4% in 2005 and 4.1% in 2010. HIV prevalence is highest in urban 
areas. Each year, 215,130 persons die from AIDS, and 56,681 children are born with HIV [14]. The main 
route of HIV transmission in Nigeria is heterosexual sex. Low risk heterosexual sex contributes almost 
50% of new infections [14]. Other modes of infection are injecting drug use, female sex workers and 
men who have sex with men, which contribute almost 25% of new infections. Illiteracy, poverty, sexually 
transmitted infections, low condom use and a lack of perceived personal risk have been identified as 
drivers of the HIV epidemic in Nigeria.  
The HIV response in Nigeria was established in 1986, and was health sector driven. In 2000, a 
multi-sectoral response commenced. Antiretroviral therapy (ART) in Nigeria began in 2002, with a free 
ART program introduced in 2006. By December 2012, there were 566 ART facilities in Nigeria (up from 
20 sites in 2002) providing treatment to 491,021 of the about 1.66 million persons in need of treatment 
[15]. 
The PMTCT program started in 2002 with six sites.  By 2013, 5622 sites provided PMTCT services 
[16]. Guidelines to prevent perinatal transmission of HIV include providing prophylaxis of three 
antiretroviral medicines to pregnant women who test positive. The key strategies of the PMTCT program 
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include testing women who are pregnant for HIV; providing antiretroviral drugs to women who are 
identified during pregnancy, or delivery, followed by ARV to the infant from birth and up to 6 weeks 
after birth, to prevent HIV transmission. Early infant diagnosis also ensures that children who are 
exposed (i.e. children born to HIV positive women) are identified early, and if HIV positive, are started 
on ART immediately.  
In 2013 only 58,000 (or 27%) HIV-positive pregnant women received ARV prophylaxis to prevent 
transmitting the virus to their unborn or breastfeeding children [16]. Yet, 10% of new infections in 
Nigeria are due to mother to child transmission (MTCT) [15]. Spectrum modeling suggests that MTCT 
accounted for 24.5% of new infections in 2011. The main challenge to PMTCT service delivery is that 
only 35.8% of women deliver in health facilities where these services are provided, even though up to 
60.6% of pregnant women attend antenatal clinics [17]. Also of the many women who are tested for 
HIV, fewer receive their HIV results, and far fewer commence ARV to prevent HIV transmission to their 
infants during pregnancy, delivery or breastfeeding.  
Institute of Human Virology Nigeria  
The Institute of Human Virology Nigeria  (IHVN) is an indigenous nongovernmental organization, which 
until 2010 was affiliated with the University of Maryland Baltimore USA to implement the AIDS Care and 
Treatment in Nigeria (ACTION) program that was funded by the US President’s Emergency Plan for AIDS 
Relief (PEPFAR). IHVN’s pediatric ART program started in 2006. As at January 2012 IHVN’s follow-on 
ACTIONPLUS pediatric ART program supported 36 health facilities in 18 of the 36 states in Nigeria and 
the FCT. Of the 89,509 persons on ART in 2012 the IHVN supported sites, 5,265 were children (0- 14 
years).  
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Structure of this dissertation 
The findings from this study are presented as follows in this dissertation: Chapter 2 presents the studies 
included in the literature review. Chapter 3 describes the study methods, while Chapter 4 presents the 
findings from the quantitative component of the study. These include the prevalence, patterns and 
predictors of HIV disclosure to children at the pediatric clinic at the University of Abuja Teaching 
Hospital (UATH). Chapter 4 also presents the limited analyses that could be done on the relationship 
between disclosure and health outcomes. (There were limited data on patient CD4 count, viral load and 
opportunistic infections in the patient paper and electronic medical records). Chapter 5 contains the 
findings from the qualitative component of the study. It presents the context and process of HIV 
disclosure to children. Chapter 6 – the plan for change - is a summary of the proposed strategies for 
disseminating the findings from the study in order to influence policy on pediatric HIV disclosure in 
Nigeria, and sub Saharan Africa, as well as programming for children living with HIV. The study 
instruments used in the study are contained in the appendices. 
 This dissertation adopted the three paper format. The following are the three papers presented 
in the dissertation: 
1. The impact of disclosure on health outcomes in HIV-infected children:  A literature review 
(Chapter 2). The target journal for publishing this paper is AIDS Care: Psychological and Socio-
medical Aspects of AIDS/HIV. 
2. Patterns, prevalence and predictors of pediatric disclosure among HIV-infected Nigerian children 
on treatment (Chapter 4). The target journal for publishing this paper is the Journal of the 
International AIDS Society.  
3. The context and process of pediatric HIV disclosure among HIV-infected Nigerian children on 
treatment (Chapter 5). The target journal for publishing this paper is AIDS Care: Psychological 
and Socio-medical Aspects of AIDS/HIV.  
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CHAPTER 2 
THE IMPACT OF DISCLOSURE ON HEALTH OUTCOMES IN HIV-INFECTED CHILDREN:  
 A LITERATURE REVIEW 
INTRODUCTION 
Ninety percent of the 2.5 million children infected with HIV live in Sub-Saharan Africa (SSA) [1]. Despite 
significant increases in access to antiretroviral drugs (ARV), Prevention of Mother-to-Child (PMTCT) 
programs in resource-limited countries are fraught with major challenges and coverage is not complete.   
Consequently, many children continue to be infected perinatally with HIV.  In 2014, there were 220,000 
new HIV infections in children 0-14 years globally. Of these, 190,000 were in SSA [2], and Nigeria 
contributed 60,000 of these in 2012 [3]. However, as a result of ARV access, these children are living 
longer [4]. Thus, a generation of children and children living with HIV (CLHIV) is coming of age. As these 
children approach adolescence, many of them have not been disclosed to, i.e. they have not been told 
they are living with HIV. The term disclosure, in this context, refers to informing children that they have 
HIV. World Health Organisation Guideline on HIV Counselling for Children up to 12 years of Age 
recommends that children of school age (6-12 years) be told they have HIV [5].  The American Academy 
of Pediatrics also recommends HIV status disclosure to school aged children [6]. 
Disclosure prevalence from four studies in developing countries ranged from 29% to 62 % [4]. 
Vaz et al. [4] reported only 3% pediatric disclosure in their study in the Democratic Republic of Congo, 
while Vreeman et al. [7] also reported almost 100% non-disclosure. More recent studies on SSA have 
similarly reported low disclosure rates  - 13.5% (Nigeria), 21% (Ghana), 17.4% and 39.5% (Ethiopia), 19% 
and 26% (Kenya), and 32.6% (Cote d’Ivoire) [8-14]. Factors that influence pediatric disclosure include 
child’s age and cognitive development, concerns around antiretroviral treatment (ART) adherence, 
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imminent onset of sexual activity, and the need to protect others from infection. Benefits of pediatric 
disclosure include improved adherence to ART, and psychosocial well-being and mental health. Despite 
these benefits of disclosure, nondisclosure remains high because disclosure carries with it a negative 
exposure due to the association of HIV positive status and sex (promiscuity). Disclosure of HIV status to 
children living with HIV, or to partners, remains “navigation in a moral field” [15]. Therefore to protect 
the family name and one’s reputation, and avoid rejection and discrimination many choose not to 
disclose HIV status to children.  
Literature on disclosure suggests that when disclosure does happen, it is not done in a 
systematic way [4]. The process remains largely context dependent. It is also not clear whether there are 
policies and guidelines on pediatric disclosure in many countries. Yet, disclosure could be a potent force 
in the prevention and control of HIV infection to those not infected, and for those who are already 
infected it provides an opportunity for improved quality of life for the HIV infected and their families, 
and slowing of disease progression. 
This literature review, therefore, aimed to explore the association between pediatric disclosure 
i.e. disclosure of child’s seropositive HIV status, and health outcomes among children living with HIV: Is 
there any correlation between HIV disclosure and improved or worsened health – physical, 
psychological, or other dimensions of health? The review also aimed to assess the prevalence, patterns 
and predictors of HIV status disclosure to children. The literature review also looked at non-disclosure to 
determine if there were any relevant ethical issues to consider in pediatric disclosure, and how these 
were applicable to the SSA context; and how disclosure policies and guidelines could facilitate or 
support HIV control measures.  
While the literature review looked at pediatric HIV disclosure in all contexts, particular interest 
was on SSA, since most CLHIV reside in this part of the world. As much as possible, the review also 
attempted to tease out any regional differences, if any, on health outcomes and HIV disclosure. 
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METHOD 
Search Process: A multi-stage process was used to search for data on disclosure of HIV status to children 
living with HIV in 2011. First, the ISI Social Science website database was searched for relevant articles. 
This was followed by a search in the bibliography sections of these articles for other publications that 
were relevant i.e. pursuing references of references. Articles pertinent to the research question, “The 
Impact of Disclosure on Health Outcomes for HIV-Infected Children,” were searched for in the ISI Web of 
Science database, using the terms arrangement as follows: 
((Child* OR adolescent OR p*diatric OR perinatal*) AND (HIV OR status) AND (Diclos*)) 
Child(ren) 
OR 
Pediatric 
OR 
Paediatric 
OR 
Adolescent 
OR 
Perinatal(ly) 
AND HIV 
 
OR 
 
Status 
AND Disclosure 
 
OR 
 
Disclosing 
 
The search strategy was repeated in 2014 for additional peer reviewed articles that may have been 
published since the last search. This second search was limited to studies conducted on SSA. 
Inclusion criteria: Only articles on studies published in peer-reviewed journals were included in the 
review. Articles had to focus on disclosure of HIV status to children (persons under 18 years) living with 
HIV, and be based on primary data collection. Since it was anticipated that there would be a wealth of 
available primary data on the subject (and there were) secondary data (systematic reviews or meta-
analyses) were not included in the review. Commentaries were also not included in the review. Studies 
could be qualitative or quantitative, or mixed methods. However, they had to contain an explicit 
definition of the term disclosure or a clear indication that children knew their positive HIV serostatus, 
and the consequences and outcomes of such disclosure as a dependent or independent variable. Studies 
could include reasons for disclosure, the process of disclosure and by whom. Studies could also focus on 
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only children to whom their status had been disclosed to them, or also contain a control group whose 
status was not disclosed to them. The most important element was that studies were limited to those 
where full disclosure of HIV status was done. In other words, children knew they were HIV positive. “A 
child was considered to be fully informed of his or her status if the term HIV, AIDS, or any local term 
specifically associated with HIV/AIDS has been used in a discussion with the child about the child’s 
health” [4]. Reviewed articles also had to include a clear description of the population size, data 
collection process, the independent and dependent variables, and how data were analyzed. 
Exclusion criteria: Studies on disclosure of other childhood illnesses other than HIV were not included. 
Also disclosure studies of status of others – adults, parents, and so on - were not included. Only studies 
where disclosure was by a parent, caregiver or health care provider were included. Studies where 
children learned of their serostatus inadvertently through sources other than parents, caregivers or 
health care providers were not included in the review, as it is believed that the effect of such disclosure 
may be different from that through a controlled environment through a parent/caregiver or health 
provider. 
Studies where there was only partial disclosure i.e. discussing with children about the child’s 
health in general terms, without specific mention of HIV or AIDS, and non-English language articles were 
not included. There was no time limit or country or regional restriction to the studies or publications 
included in the review. 
Identified studies: The 2011 search yielded a total of 426 articles. After a review of the article titles, 242 
articles that were not relevant to the research question were eliminated from further search. Abstracts 
for the remaining 184 articles were reviewed, after which a further 144 articles were excluded because 
of content (135), three were in French, and the rest were editorials, articles and letters. Another three 
articles could not be retrieved from the UNC library. Full text of the 44 articles that appeared relevant to 
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the research question was then reviewed for eligibility. Fifteen articles met the inclusion criteria, but 
two articles were publications on the same study, so one was eliminated from further review.  
 
Figure 2.1: Flow Chart of the Identification of Studies included in the Review 
 
Identification         
 
 
Screening    
 
 
Eligibility    
 
 
Included         
 
 
An additional eight studies were identified from the 2014 search. While all reported disclosure rates and 
factors that affected status disclosure, only one study assessed the association between disclosure and 
health outcomes, namely ART adherence, and stigma and depression [13], and was included in the 
review.  
Due to the limited number of studies that met the inclusion criteria, the inclusion of articles did 
not focus on their internal validity based on the study approaches, strong statistical power, or an 
experimental approach. Nor were the external validity of articles a limiting factor in terms of a large 
study population, random sample, and explicit analysis of context and intervention factors for which 
generalization is possible. (The impact is discussed under the Discussion section, as a limitation of the 
studies in this review).  
144 abstracts excluded because 
of content (135), language (3), 
were editorials (2), letters (1), 
article not available from UNC 
HSL (3) 
184 abstracts screened 
44 full text articles assessed 
for eligibility 
30 full text articles were excluded 
(2 on the same studies, 2 
literature reviews) 
14 studies included in review 
426 articles identified 
through searching the ISI 
Web of Science 
3 articles identified 
through “snowballing” 
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Data extraction: The following data were then extracted from the studies that met the inclusion criteria. 
In addition to information on authors, year of article, and country where study was conducted, 
participant characteristics (study participants, children’s age), and study characteristics (sample size, 
study type and design, type of analysis, dependent and independent variables, results, statistics, 
significance and study validity information), and the health outcomes of disclosure were extracted from 
the studies. 
RESULTS 
Five major health outcomes emerged from children’s knowledge of their seropositive status (Table 2.1): 
Disease progression (CD4 count, death) and other physical outcomes; Adherence to antiretroviral 
treatment (ART); Self-esteem, mental, emotional and other psychosocial outcomes; and Sexual and 
reproductive health, including HIV prevention outcomes. The latter was particularly relevant to another 
theme that emerged from the results, that was not in the original review conceptualization – disclosure 
of status by the children to friends and sexual partners. 
Physical outcomes 
Three studies described the physical health outcomes of status disclosure in children living with HIV 
(CLHIV). The first, a comparison study of 325 Romanian children 5 – 17 years on antiretroviral treatment, 
some of whom had been told their serostatus and others who were non-disclosed, showed a significant 
difference in disease progression as measured by decline in CD4 % and death [16].  A Kaplan Meier 
survival analysis showed that non-disclosed children were more likely to die (p=0.03). Although there 
was no significant difference in CD4 decline, the trend was the same, with a greater proportion of non-
disclosed children experiencing CD4 decline (p=0.26), and were more likely to experience death or CD4 
decline than children who knew their status (p=0.03).  
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A 1997 multicenter Pediatric Spectrum of Disease (PSD) active surveillance study of 100 
American school CLHIV in Massachusetts, however, did not show any association between clinical 
severity of children’s symptoms (CDC clinical stage of mild, moderate or severe) with whether a child 
was told of his or her disease status [17]. Forty-eight percent of children with severe symptoms had 
been told of their status compared to 39% of children with mild to moderate symptoms. Similarly, 
Vreeman et al. did not find any associations between disclosure status and clinical indicators like CD4 
count and WHO disease stage in their study of 792 caregiver-child dyads in Kenya [13]. 
Adherence to treatment 
One would have expected more studies on the effect of disclosure on treatment adherence, since this is 
the reason most often given for promoting status disclosure. However, only three studies focused on 
the effect of disclosure of child’s status to the child and treatment adherence. The quasi experimental 
study of disclosure’s effect on 40 children on ART in Puerto Rico showed that over half (58%, 95% CI 41% 
- 73%) self-reported that knowing their status had helped them develop better adherence to their 
medicines [18]. All 25 adolescents and their caregivers in the South African qualitative study reported 
good adherence as a result of the children knowing their status [19].  In the Kenya study by Vreeman et 
al., disclosure status was not associated with adherence as reported on the clinical encounter form or by 
caregivers. However, disclosure was associated with child-reported adherence (p= .03), and disclosed 
children reported more non-adherence than non-disclosed children [13]. 
Mental and Psychosocial outcomes 
Understandably, majority of the studies reviewed focused on the mental, emotional and other 
psychosocial effects of disclosure, since this is one of the reasons often cited for both disclosure and 
non-disclosure to children. Nine articles, four of which were on SSA, focused on this health outcome. 
While two of the articles were on the same Pediatric AIDS Clinical Trials Group (PACTG) 219 C 
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prospective cohort study, the authors and foci of the two articles were different, and were therefore 
included as separate studies in this review. The first PACTG 219 C study focused on the effect of HIV 
disclosure on the quality of life (QoL) based on 2423 study visits by 395 CLHIV in USA [20]. The study 
showed that there were no statistically significant differences between pre-disclosure and post-
disclosure quality of life domains (general health perception, symptom distress, psychological status, 
health care utilization, physical functioning, and social/role functioning). Disclosure was not significantly 
associated with QoL in crude or adjusted mixed effects model analyses, indicating that QoL did not 
change because of disclosure of HIV infection status. Caregivers reported lower QoL scores after 
disclosure for all domains except social/role functioning, although these differences were not significant. 
The other PACTG 219C study, however, reported that CLHIV were at increased risk of psychiatric 
hospitalization than the general pediatric population, and knowledge of seropositive status was 
significantly associated with increased risks of admission in this population [21]. Multivariate analysis 
showed that CLHIV who were aware of their status were six times more likely to be hospitalized because 
of psychiatric illnesses compared to those who were not, mostly for depression and behavioral disorders 
– which are precursors for more severe pathologic conditions, such as bipolar disorder and suicide.  
The progression of patients’ self-reported emotions after disclosure ranged from sadness 
immediately after disclosure to normalcy by most youth (70%, N=40, p<0.05) after six months of 
disclosure. However, one patient remained depressed six months after depression [18]. Lester et al., 
however, showed that disclosure of status may not necessarily minimize emotional distress, as HIV 
disclosure was associated with increased parent-rated anxiety in HIV-infected children (p=.04) [22]. This 
points to the need for further studies on the appropriate timing and type of disclosure of pediatric HIV 
[22]. 
A UK study of CLHIV [23] did not show any statistical difference in psychological (emotional and 
behavioral) adjustment than the general population, as measured by the Strengths and Difficulties 
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Questionnaire (SDQ score of 0.56 which approaches acceptability levels). However, a similar study in 
Zambia using the same SDQ methodology [24] showed increased mental health problems (OR = 2.1), 
especially emotional symptoms (OR = 3.6) and peer problems (OR = 7.1). Univariate analysis showed no 
difference between children who knew their HIV status and those who were aware of their status. 
However, the non-disclosure group was twice as likely to experience emotional difficulties (OR=2.63, 
95% CI: 1.11 to 6.26).  
The South African study by Petersen et al. [19] showed similar emotional difficulties for children 
who received a positive HIV diagnosis. Thirty-six percent (N=9) reported withdrawing from their friends 
and social activities, and over 50% reported internalized stigma. But for the eight children in an 
exploratory study in the Democratic Republic of Congo who knew their status, despite the negative 
emotions experienced at the time of disclosure, there were no (subsequent) negative effects of knowing 
their status [4]. Instead the benefits of knowing their status included no longer worrying so they could 
avoid being sicker, as well as being able to protect others from HIV infection. 
The Kenya study of 792 caregiver-CLHIV dyads found that disclosed children experienced higher 
rates of HIV-related stigma and depression symptoms although only depression symptoms were 
significantly associated with disclosure in multivariate regression (OR =2.6, 95% CI 1.1-6.2)  [13]. 
Sexual and reproductive health 
Young CLHIV receive health services under pediatric care, and are often not being adequately prepared 
for adult life. Only one study focused on sexual and reproductive health (SRH) issues for CLHIV. In terms 
of SRH services, especially in relation to preventive practices, such as condom or contraceptive use 
among sexually active CLHIV, only 37% (N=236) of CLHIV in a Population Council study in Uganda 
reported using a condom at time of first sex [25]. Only 50% used any form of contraception in current or 
previous relationships, and 47% reported current condom use (All figures were statistically significant, 
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p<0.05). These are relatively high use rates compared to the general population, and especially for 
adolescent population [25]. 
Disclosure of status to others by children 
Research has shown that self-disclosure of traumatic or secretive information produces observable 
health benefits [26]. In this regard, the focus is on whether self-disclosure influences health outcomes 
such as the immune response, psychological well-being and other health outcomes. Four studies on this 
issue met the inclusion criteria. Sherman et al. observed a small but significant increase in CD4 percent - 
a predictor for disease progression (mean = +1.78, SD =5.03, t (63) =2.83, p<0.01) in children who had 
self-disclosed to friends. This increase was still significant even when child’s age was controlled in the 
analysis. An ANOVA for these data were also significant (F (2,60) =4.28, p<0.05). Psychological well-being 
as measured by self-concept did not approach significance (F (2,60) =0.56, p>.15). Similar ANOVA 
analysis for changes in behavioral problems also did not approach significance (F (2, 5) = 0.69, p>0.15).  
Battles and Weiner [27] examined the psychosocial factors associated with long-term survival of 
pediatric HIV in 80 parent-child dyads of disclosed children. Pearson product moment correlations 
showed that disclosure was positively related to social support (r=.35, p<0.05), self-competence (r=.35, 
p=.08), and decreased problem behavior (r= -.21, p<=.08) except for public disclosure (i.e. disclosure to 
the media), where the Student’s t-test showed a negative association with self-competence (F=3.5, 
p<0.05). 
A small scale qualitative study of six program participants at a transition to adulthood program 
embedded in the National Health Service family clinic in the UK showed that participation in the 
transition program facilitated a positive attitude towards medication, and hope for the future. However, 
respondents reported not disclosing their status to others, including sexual partners [28]. 
DISCUSSION 
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Findings 
The first major finding from this review is that HIV disclosure to children living with HIV has an effect on 
disease progression in terms of clinical severity of symptoms, CD4 percent and ultimately death. While 
the Romanian comparison study showed that HIV disclosure led to a slowing down of disease 
progression through higher CD4 percent [16], the US study did not show any impact of HIV disclosure on 
clinical severity of disease symptoms [17], nor did the Kenya study show any association with CD4 count 
[13]. It may be argued that the US study used a limited sample size, and no information on the statistical 
significance of the results was presented, compared to the more rigorous analysis of the Romanian 
study, which included adjusting for confounders. All the same, more prospective studies  
 
Table 2.1: Overview of studies included in the literature review 
  Authors Study Goal Country  
Sample 
size Study Type Study Design Type of analysis 
Independen
t variable 
Dependent 
variable Results 
A A: Physical outcomes                 
1 
Ferris et al., 2007 
[16] 
Disclosure effect 
on disease 
progression Romania 325 
Quantitative 
and 
Qualitative 
Comparison 
groups - 
disclosed 
versus non-
disclosed; 
retrospective 
database 
analysis 
Student t tests, 
chi square test, 
Fischer's Exact 
test, Cox 
regression models 
HIV 
disclosure 
Death, CD4 
decline, 
combined, 
time to HIV 
disease 
progression 
Death =4.9% vs 11.0%; CD4 
17.3% vs 21.3%; Cox 
regression Hazard ration 0.60 
(p=0.03).  no statistical 
significant difference in CD4 
decline between disclosed and 
non-disclosed children (p=0.26); 
non-disclosed children more 
likely to experience disease 
progression through death or 
CD4 decline (p=0.03). non-
disclosed children were more 
likely to die () 
2 
Cohen et al., 1997 
[17] 
Issues related to 
school 
attendance and 
HIV disclosure USA 100 Surveillance 
Abstraction of 
medical records 
Logistic 
regression, using 
SAS, X2,  
HIV 
disclosure 
Clinical 
severity of 
symptoms 
49% of children with severe 
symptoms have been told 
compared with 39% of children 
with mild and moderate 
symptoms. Clinical severity of 
child's symptoms not associated 
with child's knowledge of status 
or not 
3 
Vreeman et al., 2014 
[13] 
Association 
between 
disclosure and 
key child level 
demographic, 
clinical, and 
psychosocial 
characteristics Kenya 
792 
caregiver-
child 
dyads 
Cross – 
sectional, 
quantitative 
Comparison 
groups – 
disclosed and 
non-disclosed 
children, 
medical chart 
review 
Pearson’s chi-
squared test, 
multivariate 
logistic regression 
with odds ratio 
HIV 
disclosure 
Clinical 
characteristics 
– adherence, 
CD4 count, 
CD4 %, WHO 
staging 
No association between 
disclosure and WHO staging 
(p=0.079), and CD4 count 
 
  
B: Adherence to 
treatment                   
1 
Blasini et al., 2004 
[18] Disclosure model  Puerto Rico 40 CLHIV Quantitative 
Quasi 
experimental, 
before after,  
Fisher's exact 
test, report p 
values for two-
tailed test 
HIV 
disclosure 
Sadness, 
worry, 
insecurity and 
other 
psychosocial 
outcomes 
42% CLHIV felt sad immediately 
after disclosure. At 6 months, 
70% youth reported normalcy. 
One patient reported depression 
after 6 months. 58%, 95% CI 
reported better adherence 
1
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2 
Petersen et al., 2010 
[19] 
Examine 
psychosocial 
challenges and 
protective factors South Africa 25 Qualitative   
thematic using 
NVivo8 
HIV 
disclosure 
Identity, 
psychosocial 
issues, 
internalised 
stigma 
22 CLHIV knowing status 
emotionally difficult; 36% (9) 
withdrew from friends; >50% 
showed internalised stigma; 
100% good adherence 
3 
Vreeman et al., 2014 
[13] 
Association 
between 
disclosure and 
key child level 
demographic, 
clinical, and 
psychosocial 
characteristics Kenya 
792 
caregiver-
child 
dyads 
Cross – 
sectional, 
quantitative 
Comparison 
groups – 
disclosed and 
non-disclosed 
children, 
medical chart 
review 
Pearson’s chi-
squared test, 
multivariate 
logistic regression 
with odds ratio 
HIV 
disclosure 
Clinical 
characteristics 
– adherence, 
CD4 count, 
CD4 %, WHO 
staging 
Disclosure was associated with 
child reported adherence 
(p=0.03) with disclosed children 
reporting more non-adherence 
than non-disclosed children 
 C: Mental and Psychosocial outcomes        
1 Vaz et al., 2010 [4] 
Explore events 
before, during 
and after 
disclosure 
Democratic 
Republic of 
Congo 8 Qualitative     
HIV 
disclosure 
Worry; protect 
others from 
infection 
Children felt sad immediately 
after disclosure; but later did not 
state any negative effect of 
knowing their status; benefits 
included not being worried and 
avoid being sicker; being able to 
protect others. 
2 
Sopena et al., 2011 
[23] 
Psychological 
adjustment 
United 
Kingdom  30 Quantitative 
Correlational 
design,  
Pearson 
correlations 
HIV 
disclosure 
Psychological 
adjustment 
(behavioural 
and 
emotional); 
disclosure to 
others 
Psychological adjustment score 
= -1.03. p>0.05, no significant 
differences btw CLHIV and 
general UK population 
3 
Menon et al., 2007 
[24] 
Relationship 
between 
disclosure and 
mental health Zambia 127 
Quantitative, 
Qualitative 
Cross sectional 
survey 
Mann Whitney U 
test, Spearman, 
content analysis 
HIV 
disclosure 
Emotional, 
conduct, 
hyperactivity, 
peer relations, 
pro-social 
behaviour 
Difficulties 29.1% (N=37) OR2.1 
(CI 95%); increased mental 
problem OR=2.1), peer problem 
(OR=7.1), emotional symptoms 
(3.6). Those whose status not 
disclosed more likely to score 
abnormal range for emotional 
difficulties (OR=2.63, 95% CI). 
Disclosure did not have 
negative impact on mental 
health 
20
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4 
Gaughan et al., 
2004 [21] 
Examine long 
term outcomes 
among CLHIV 
and nonCLHIV USA 
2298 
CLHIV, 
1021 
nonCLHIV Quantitative 
Prospective 
cohort study 
(PACTG) 219C 
Relative risks 
using Poisson 
rate parameters; 
Cox proportional 
hazards 
regression 
techniques 
HIV 
disclosure 
Psychiatric 
hospitalisation 
CLHIV incidence of 6.17 cases 
per 1000 person years (CI 95%) 
versus 1.7 cases per 1000 
person years for non 
CLHIV.CLHIV aware of their 
status were 6 times more likely 
to be hospitalised due to 
psychiatric illnesses, compared 
to CLHIV not aware of their 
status (hazard ratio 6.13). 
Depression and behavioural 
disorders were most common 
reasons for hospitalisation. 
knowledge of HIV status 
significantly associated with 
increased risk of psychiatric 
hospitalisation 
5 
Butler et al., 2009 
[20] 
Impact of 
disclosure on 
quality of life USA 
395 CLHIV 
(2423 
study 
visits) Quantitative 
Prospective 
cohort study  
Spearman’s, 
Pearson's, 
Wilcoxon signed 
rank tests 
HIV 
disclosure 
QoL (general 
health 
perception; 
symptom 
distress; 
psychological 
status, 
physical 
functioning; 
social/role 
functioning, 
health care 
utilisation 
Health perception 0.410 
(P=.70); symptom distress 
0.588 (P=.31), psych status 
0.005 (P>0.999), physical 
functioning 0.536 (P=0.79); 
social/role functioning 0.380 
(p=0.69); health care use -0.275 
(p=.61). No statistically 
significant difference between 
pre and post disclosure quality 
of life; caregivers reported lower 
QoL scores after disclosure, 
though not stat significant 
6 
Lester et al., 2002 
[22] 
Explore factors 
associated with 
emotional 
distress in CLHIV USA 51 
Quantitative 
and 
Qualitative   
Content data 
analysis; Kaplan 
Meier survival 
curves, multiple 
linear regression 
HIV 
disclosure 
Child's parent 
rated anxiety 
level 
Higher anxiety significantly 
associated with HIV disclosure; 
(t=2.15, p=.04). Child rated 
depression or anxiety showed 
no association with HIV 
disclosure. Disclosure does not 
necessarily minimise emotional 
distress 
7 
Blasini et al., 2004 
[18] Disclosure model  Puerto Rico 40 CLHIV Quantitative 
quasi 
experimental, 
before after,  
Fisher's exact 
test, report p 
values for two-
tailed test 
HIV 
disclosure 
Sadness, 
worry, 
insecurity and 
other 
psychosocial 
outcomes 
42% CLHIV felt sad immediately 
after disclosure. At 6 months, 
70% youth reported normalcy. 
One patient reported depression 
after 6 months. 58%, 95% CI 
reported better adherence 
8 
Petersen, et al., 
2010 [19] 
Examine 
psychosocial 
challenges and 
protective factors South Africa 25 Qualitative   
Thematic using 
NVivo8 
HIV 
disclosure 
Identity, 
psychosocial 
issues, 
internalised 
stigma 
22 CLHIV knowing status 
emotionally difficult; 36% (9) 
withdrew from friends; >50% 
showed internalised stigma; 
100% good adherence 
215 
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9 
Vreeman et al., 2014 
[13] 
Association 
between 
disclosure and 
key child level 
demographic, 
clinical, and 
psychosocial 
characteristics Kenya 
792 
caregiver-
child 
dyads 
Cross – 
sectional, 
quantitative 
Comparison 
groups – 
disclosed and 
non-disclosed 
children, 
medical chart 
review 
Pearson’s chi-
squared test, 
multivariate 
logistic regression 
with odds ratio 
HIV 
disclosure 
Clinical 
characteristics 
– adherence, 
CD4 count, 
CD4 %, WHO 
staging 
caregiver-reported depression 
symptoms (OR 2.63, 95%CI 
1.12–6.20) were significantly 
associated with knowing one’s 
status 
 
  D: Sexual and reproductive health outcomes             
1 
Birungi, et al., 2009 
[25] 
Sexual 
expressions of 
CLHIV Uganda 740 
Qualitative 
and 
Quantitative   
Quantitative - 
cross tabs, chi 
square, 
significance tests 
of proportions; 
Qualitative - 
content analysis 
HIV 
disclosure 
Condom use, 
contraceptive 
use; status 
disclosure to 
others 
Condom use 37%; 
contraception 50%; disclosure 
to partner 38%,  p<0.05; 
condom use 37%; contraception 
50%; disclosure to partner 38% 
  
E. Child's 
disclosure of 
status to others                   
1 
Sherman et al., 2000 
[26] 
Physiological and 
psychological 
consequences of 
children's self-
disclosure USA 
64 CLHIV-
caregiver 
dyads Quantitative 
Before-after, 
comparison 
groups 
Univariate 
ANOVA, X2, 
Tukey's Honestly 
Significant 
Difference test,  
Child's self-
disclosure 
CD4% 
(disease 
progression), 
self-concept, 
behavioural 
problems 
Disease progression: CD4% 
showed small but significant 
increase (mean =+1.78, 
SD=5.03); t(63)=2.83, p<.01); 
ANOVA data significant: 
F(2,60)=4.28, p<.05; Self-
concept did not approach 
significance, F(2,60)=0.56, 
p>.15; Behavioural problems 
also did not approach 
significance, F(2,57)=0.69, 
p>.15. Even with child's age 
controlled, self-disclosure to 
friends was associated with 
significantly greater CD4% 
change 
2 
Campbell et al., 
2010 [28] 
Impact of 
transition 
program UK 6 Qualitative   
Thematic 
approach 
HIV 
disclosure 
Disclosure to 
others; hopes 
for the future 
100% difficulty disclosing to 
others; hopeful about future # 
not included) 
22
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3 
Battles et al., 2002 
[27] 
Examine 
psychosocial 
factors 
associated with 
long term survival 
of pediatric HIV. USA 
80 parent- 
CLHIV 
dyads Quantitative 
Descriptive. 
Longitudinal 
study 
Pearson product 
moment relations, 
Chi-square, 
Student's t 
HIV 
disclosure 
Child 
behaviour, 
self-
perception,  
Disclosure significant positive 
association with peer social 
support (r=.35, p<.05), 
marginally negatively 
associated with aggressive 
behaviour (r=-.21, p=.08, 
marginally positively associated 
with perceived social self-
competence (r=.35, p=.08. 
Pearson product-moment 
correlations showed disclosure 
was positively related to social 
support, self-competence, 
decreased problem behaviour, 
except for public disclosure, 
where Student t showed 
negative association with global 
self-competence. 
4 
Birungi, et al., 2009 
[25] 
Sexual 
expressions of 
CLHIV Uganda 740 
Qualitative 
and 
Quantitative   
Quantitative - 
cross tabs, chi 
square, 
significance tests 
of proportions; 
Qualitative - 
content analysis 
HIV 
disclosure 
Condom use, 
contraceptive 
use; status 
disclosure to 
others 
Condom use 37%; 
contraception 50%; disclosure 
to partner 38%; p<0.05; condom 
use 37%; contraception 50%; 
disclosure to partner 38% 
  CLHIV = Children living with HIV        
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on larger sample CLHIV populations are needed to draw any definitive conclusions on the effects of HIV 
disclosure on disease progression and severity. 
The second major health outcome of HIV disclosure was ART treatment adherence. Since ART is 
life long, one recurring challenge for caregivers and CLHIV is how to maintain treatment adherence. 
With ART, a high adherence level of up to 95% or more is necessary to avoid drug resistance and its very 
serious consequence of treatment failure. As such ART adherence is a critical factor in managing HIV 
infection. One would, therefore, have expected more studies on the effect of disclosure on CLHIV 
treatment adherence, since this is the reason most often given for promoting status disclosure. 
However, only three studies focused on the effect of disclosure of child’s status to the child and 
treatment adherence [13, 18, 19]. As expected, the children and their caregivers reported improved 
adherence to treatment as a result of the children knowing their HIV status. Incidentally, the small 
sample sizes (40 and 25) and the less than rigorous analyses limit any broad conclusions on the impact 
of disclosure on treatment adherence. This review, therefore, calls for more studies considering the 
importance of adherence on HIV treatment. 
Understandably, majority of the studies focused on the mental, emotional and other 
psychosocial effects of disclosure, since this is one of the reasons often cited for both disclosure and 
non-disclosure to children. Five of the nine studies in the review reported a negative impact of 
disclosure on some aspect of mental health, while four did not. Only three of the studies (two in the US, 
and from the same PACTG 219C prospective study and one from Kenya) had sufficiently large sample 
sizes, but both US studies reached differing conclusions. While Butler’s 2009 study [20] of 2423 visits of 
395 CLHIV did not show any statistically significant difference between pre and post HIV disclosure on 
QoL (general health perception; symptom distress; psychological status, physical functioning; social/role 
functioning, health care utilization), Gaughan et al. [21] showed in their study of 2298 CLHIV and 1021 
children not living with HIV that knowledge of HIV status was significantly associated with increased risk 
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of psychiatric hospitalization, with CLHIV who were aware of their status being six times more likely to 
be hospitalized due to psychiatric illnesses, compared to CLHIV not aware of their status (hazard ratio 
6.13). It is not clear what the reasons could be for the different conclusions from the two studies. A 
possible explanation for the different conclusions could be that while Butler et al. measured pre and 
post disclosure QoL changes in the same CLHIV, Gaughan’s study compared psychiatric hospitalization in 
HIV disclosed CLHIV to children not living with HIV. The experience of a significant life event (such as 
death in the family, beginning school) also contributed to the positive correlation between disclosure 
and hospitalization, and may partly explain the contrasting conclusions from the studies.  Although the 
Kenya study by Vreeman [13] had a large sample of 792, and reported higher rates of depression and 
stigma among disclosed children, the study was not designed to assess the impact by pre- and post-
disclosure characteristics. 
  The only study on the impact of disclosure on SRH outcome showed a positive and statistically 
significant correlation between disclosure and condom use and contraceptive use rates that are even 
much higher than the general population rates for adolescents, in addition to status disclosure to 
partners [25]. Obviously, this is a less well researched area and further studies are needed [25]. 
Finally, a child’s knowledge of their HIV status, and the child’s subsequent disclosure of their 
status to others (friends and sexual partners) had an effect on child’s health outcomes. Three of the four 
studies showed a positive correlation between child’s disclosure of their status on the child’s health 
outcome, such as increase in CD4 percent [26], increased self-competence and decrease in problem 
behaviour [27]. The UK study of six children showed none of the children disclosed their status to sexual 
partners [28]. 
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Implications and Recommendations 
Disclosure of a child’s HIV status to the child has value in terms of positive health outcomes for the child, 
such as better adherence and slower disease progression [16]. Yet, there does not seem to be a 
systematic or coherent system for child disclosure. One recommendation from this review, therefore, is 
the need for government and program policies and guidelines that will promote child HIV disclosure in 
order to address the current low rates of disclosure in SSA. To date, no SSA country has developed 
detailed disclosure guidelines. However, WHO has published Guideline on HIV Counselling for Children 
up to 12 years of Age for adaptation in countries [5]. As more CLHIV are of school age, such policies and 
guidelines also need to include disclosure to education personnel in the school environment, as well as 
how to build capacity in the school environment to limit stigma and facilitate support for CLHIV in 
schools. Although the decision to inform schools of the child’s HIV status should remain a family 
decision, providers and program managers can facilitate the process and help build family capacity to do 
this [17]. 
Disclosure may not always be beneficial, as negative effects may manifest both in the short and 
longer term, such as precipitated psychiatric issues [21]. While it is not clear how much of a challenge 
this is in SSA, or whether the resulting psychiatric illness is due to HIV or other psychosocial factors, 
clinicians need to set up systems to monitor and identify warning signs of psychiatric illness, and 
establish systems for referrals for mental health services [21]. Programs that not only address clinical 
needs of children but other aspects of child well-being, including psychosocial, life skills, for instance., 
self-competence, and SRH needs, as well as psychosocial support programs for caregivers are also 
needed. 
Programs that adequately address the SRH needs of CLHIV are a clear need from this review, 
especially as many CLHIV are growing into adolescence and beginning sexual activity. It is critical to 
reorient health care providers to address their ability and willingness to provide services for HIV 
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prevention, and contraceptives to CLHIV. They also need to emphasize status disclosure, especially in 
discordant relationships (where one partner is not living with HIV), and encourage consistent condom 
use to prevent further infection of CLHIV and others [25]. 
Research gap 
Only five of the 15 studies included in this review were conducted in sub-Saharan Africa (none in West 
Africa), two of which had very small sample size of 8 and 25, and limited the ability to perform rigorous 
analyses that will also focus on causality, and not just correlations. However, currently 90% of CLHIV live 
in SSA, with ~15% of them living in Nigeria alone [1]. Clearly, therefore, a major recommendation is the 
need for more studies on SSA, especially as the different cultural, social and economic environment in 
SSA may (or may not) influence health outcomes and HIV disclosure differently.  Another 
recommendation is for more studies of larger sample size, and more rigorous analyses – not only for 
studies on SSA, but also for studies from other regions (the US and elsewhere), as nine of the 15 studies 
reviewed were of sample size 100 or less.   
Studies in this review focused mostly on children infected perinatally. However, it is not clear if 
there will be differences in health outcomes between perinatally acquired HIV and non-parental 
transmission (such as, blood transfusion, and sexual transmission) and differences in disclosure and 
health outcomes. Experiences of youth who learn of their status accidentally (outside of their families or 
health providers) also need to be studied. Programs also need a better understanding of disclosure on 
school attendance and performance, and to study the complex social needs of HIV positive children, as 
these relate to the school environment [17].  
Current studies have limited information on the disclosure process and context. There is need 
for a better understanding of the appropriate process, context, and child’s age for disclosure of status, 
and how these impact on health outcomes [4]. The WHO pediatric disclosure guidance also recommends 
28 
 
 
further research on who is best positioned to disclose to the child; and what factors can promote or act 
as barriers to disclosure [5]. Such studies could provide important information for policy development 
and guidelines on pediatric HIV disclosure. Studies of physical health outcome also need to include other 
markers of HIV disease progression, such as viral load, clinical status and/or growth velocity [16]. 
Furthermore, more studies adapted for SSA are needed that use standardized measures to assess 
emotional health. 
Limitations 
This review and the interpretation of the findings presented here have several limitations. First, only one 
database was searched. It is likely that widening the study search to additional databases, such as 
PubMed, would have yielded other relevant studies. Also, with only one reviewer, the study review 
process did not benefit from a second opinion where there were uncertainties on whether to include a 
study or not. The third limitation is the very small sample size of most of the studies. This limited the 
sophistication of analyses that could be performed by the researchers, including adjusting for 
confounders. As such, very limited conclusions can be drawn from the studies. Fourth, most of the 
studies were cross sectional. Therefore, only correlational inferences between disclosure and health 
outcomes could be made, without establishing causality.  
Fifth, key terms were not defined in most studies. While a few studies used standard tools 
developed and tested for psychometric studies [20], [21], [23], [24], in majority of the studies, it was up 
to the investigator to determine how anxiety, depression, and other key terms were defined and 
conceptualized in the studies. While CD4 count (and percent) was used as a key indicator for disease 
progression, inclusion of other indicators, such as the number and severity of adverse health events as 
stronger indicators of HIV disease progression, would have made the studies better [16]. Finally, most of 
the studies included in the review were conducted outside sub-Saharan Africa. It is not clear if similar 
findings will be obtained if the studies are repeated within the SSA context. 
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CONCLUSION 
This review highlights that HIV disclosure to CLHIV does have an effect on health outcomes – physical, 
psychological, treatment adherence, SRH, and status disclosure to others - albeit the different studies 
did not always reach the same conclusions. There is a very clear need for more studies on SSA, the 
region where the majority of CLHIV resides, as well as more rigorous and longitudinal studies, with 
larger study samples that will allow for more sophisticated analyses that can establish causality. 
Information from these studies would also be valuable to countries and program managers to develop 
HIV disclosure policies and guidelines, and programs that improve the well-being of CLHIV and their 
caregivers. 
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CHAPTER 3 
METHODOLOGY 
STUDY DESIGN AND METHODS 
The cross-sectional, facility-based study consisted of (1) a quantitative evaluation that used a 
combination of primary data collection and secondary data analysis to characterize pediatric disclosure 
(defined as disclosure of child’s seropositive HIV status to the child or informing the child that s/he has 
HIV) and explored its association with health outcomes in Nigerian children; and (2) a qualitative 
component to determine the context and process of disclosure to children.   
The central research question for the quantitative component was: “Is there any association 
between pediatric HIV serostatus disclosure and the child’s health? In other words, “Does HIV disclosure 
have any association with improved or worsened child’s physical (clinical) health outcomes?“  The study 
also aimed to describe the rates and context of disclosure in a cohort of children in Nigeria. 
The main study objectives were the following: In Nigerian children on ART, 
1. Determine the rate and nature of HIV status disclosure, and identify the main agent 
(family, healthcare worker, religious leader, school staff) of disclosure to these children 
2. Determine and document the age at HIV disclosure among disclosed children  
3. Investigate locally pertinent barriers to, and facilitators of disclosure among disclosed 
and non-disclosed children 
4. Investigate associations between disclosure, and health outcomes, namely: CD4 count, 
opportunistic infections, adherence to ART, and viral load. 
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The independent variable was HIV status disclosure (disclosed or not disclosed). Key dependent 
variables that were examined were the following health outcomes: changes in CD4 count (CD4 decline), 
frequency of opportunistic infections, treatment adherence, and viral load. Due to the cross-sectional 
design of the study, it was not possible to establish causality. The focus of the study was, therefore, to 
determine if there was any association between key dependent variables and disclosure. 
Study setting 
This study was conducted at the pediatric antiretroviral treatment (ART) clinic of the University of Abuja 
Teaching Hospital (UATH) in the Federal Capital Territory Abuja, Nigeria, between February and July 
2015. This ART program is supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR) 
through the AIDS Care and Treatment in Nigeria (ACTION) program of the Institute of Human Virology 
Nigeria (IHVN). At the time of the study, a total of 401 children were currently receiving ART at the clinic. 
Of these, 35 (8.7%) were 0 – 5 years; 177 (44.1%) were 6 – 9 years; 139 (34.7%) were 10 – 14 years; and 
50 (12.5%) were ≥ 15 years.  
The pediatric clinic runs an “adolescent clinic” for older children, once every month. During this 
clinic, nurses and adherence counsellors provide health talks to the older children and their parents, 
before they meet with the doctor for consultation. The adherence counsellors also assess patient 
adherence, and provide counselling, as part of each patient’s visit to the clinic. Clinic staff (doctor, 
nurses and counsellors) also assist parents/caregivers with status disclosure to the children when 
necessary. However, there is no set pattern or procedure for how disclosure takes place. Some of these 
older children come unaccompanied to the clinic for their visits. 
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Sample size calculation 
Previous studies on disclosure in Nigeria showed very low rates of HIV disclosure to children. Therefore, 
the sample size that could capture a sufficient number of disclosed children, based on the proportion of 
children expected to be disclosed, was determined as follows: 
n = (Z/MoE)2 * p * (1-p) 
Where  
n = sample size 
z = 1.96 (95% CI) 
MoE = margin of error = 5% 
p = disclosure rate (= average 10% based on two studies in Nigeria: Brown et al. at 13% [1] and Tepper et 
al, – personal communication, at 7%)  
n = (1.96 * 1.96 * 0.10 * 0.90)/(0.05 * 0.05) 
=138.2976 
= 140 
The study therefore, sought to sample a total of 140 children. 
Study participants  
Study participants were CLHIV ≥ 6 years currently prescribed antiretroviral medications for treatment of 
HIV disease based upon relevant Nigerian Guidelines for ART [2], regardless of time of enrollment, or 
adherence to regimen, with no planned treatment interruptions at the study site. A total of 110 
parents/caregivers of these current pediatric ART patients at the clinic were selected for the study. The 
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principal investigator (PI) did not have any direct contact with the CLHIV.  The quantitative component 
of the study involved administering a questionnaire (Appendix 1) to the 110 parents/caregivers of 
pediatric ART patients; and also extracting health data on the children from their medical records, using 
a data extraction form (Appendix 2). The qualitative component consisted of in-depth interviews by use 
of an interview guide (Appendix 3) with a total of 15 parents/caregivers of disclosed children to 
determine the context and process of disclosure to the children. Only families receiving pediatric ART 
were in this clinic. It was not expected that a family will be in the clinic for any other reason besides HIV 
treatment, as this was a pediatric ART clinic.  
Participant recruitment and study procedure 
Parents/ caregivers of every eligible pediatric ART patient who visited the clinic for their regular 
consultation were invited to participate in the study. After the medical consultation with the medical 
provider (doctor), the doctor read out information from the study recruitment form pre-approved by 
both the University of North Carolina at Chapel Hill, USA and the UATH institutional review boards to the 
parents/ caregivers. The doctor asked those who agreed to participate in the study to meet with the PI. 
The PI then presented more detailed information about the study to potential participants. Thereafter, 
the PI consented the respondents who agreed to participate, and administered the study tools.  
Participants were informed they could terminate the discussion at any time. 
A: Quantitative component: The PI interviewed those who agreed to participate in the study by 
administering a semi-structured questionnaire. The questionnaire format was in sections – icebreaker, 
disclosure status (whether child had been disclosed, or not), and socio-demographic data. In closing, the 
participants were invited to ask any questions they had. 
If child was disclosed, the questionnaire asked for age at disclosure, who disclosed the child’s 
status, where status disclosure took place, and the reasons for disclosure. For parents/caregivers who 
had not disclosed to their children, the PI obtained reasons for nondisclosure and other concerns. The 
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questionnaire also captured socio-demographic data about the caregiver and the child, including 
relationship of respondent to child (i.e. if biological parent or other relative), and other characteristics of 
the family.  The administration of each questionnaire lasted about 20 - 25 minutes (including consent 
time). The interviews were conducted in the absence of the children to prevent accidental disclosure. 
Questionnaires were administered in English, Pidgin English, or Hausa through an interpreter. The PI 
continued with participant recruitment until the end of June 2015 when 110 participants had been 
recruited, and interviewed. 
For each completed questionnaire, secondary data on dependent variables – CD4 count, 
opportunistic infections, WHO staging, viral load, and treatment adherence - were later extracted from 
patient’s paper charts for all 110 children. Extracted data spanned the period 2013 to 2015. Other 
extracted data included patient age, date ART was started, and ART regimen. Not all patient paper 
medical records were available. For the eight missing paper files, patient data were extracted from 
electronic medical records (which often contained less data required for the study than paper records). 
The data extraction process did not involve any direct contact with the children or their 
parents/caregivers.  
B: Qualitative component: A total of 15 parent/caregivers of children who reported their child had been 
disclosed to during the administration of the study questionnaire (described above) were also 
interviewed using an interview guide, to determine the context of HIV disclosure to the child, in order to 
more fully understand how the disclosure process happened – how, where, who, and when, and other 
pertinent issues arising from the interview. The interview, was designed to be conversational and used 
probes to explore unexpected themes, and elicit a description of the process by which parents/ 
caregivers made the decision to disclose, and disclosed to the child, and what terms were used to 
explain the illness to the child, including whether terms “HIV”, “AIDS” or any local term was specifically 
mentioned to the child during the disclosure process. The interview also explored parent/caregiver 
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perceptions of the effects that disclosure had on the child, including but not limited to the child’s 
emotional reaction to the diagnosis. For a child to be determined as fully disclosed, the term HIV or AIDS 
or a local equivalent term must have been used in discussion with the child about the child’s health by 
parent/caregiver, or healthcare worker [3].  
The PI took notes during the interviews. No participant agreed to be audiotaped, so the 
interviews were not recorded on a voice recorder. Each interview lasted for 20 – 25 minutes. 
Pre-test: The survey questionnaire and interview guide were pretested with two parents/caregivers at 
the ART site. These were not included among the final 110 parents/caregivers in the study analyses. The 
main aim of the pretest was to enable the PI fine-tune the study instruments, if necessary. The pretest 
also involved linking the questionnaire responses to the data extraction form. At this point, patient 
identifier coding modalities were finalized to ensure confidentiality of data and protection against 
deductive disclosure of participant identity through linking the questionnaire and medical data to the 
patient.  
The questionnaire and interview were administered in the subject’s language of choice, and 
where this was different from the interviewer’s language, with the help of an interpreter, who was a 
health care worker at the clinic. Since there are many Nigerian languages, the questionnaire was not 
translated into Nigerian languages.  Since many of the parents/caregivers were themselves HIV-positive 
and receiving treatment at the adjoining adult ART clinic, it was usual for parents to leave their children 
in the pediatric clinic, while they consulted with the doctor at the adult clinic.  
In all, a total of 298 participants (not unique patients) were recruited for the study (Table 3.1). 
Patient’s name and other personal identifiers were not collected on the data collection instruments 
(questionnaire, interview guide or patient data extraction form). Instead, the patient’s file/chart number 
were noted in a notebook that was kept separately from the completed questionnaires. This enabled 
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the PI to later retrieve information on child’s CD4 count, adherence, opportunistic infection, WHO 
staging and viral load.  
Table 3.1: Overview of Study Design 
Study Focus Study 
component 
Study Tool Participant Type Max. # 
participants 
Disclosure status Quantitative Questionnaire 
(Appendix 1)  
Parents/caregivers of 
CLHIV 
140 
 Quantitative Data Extraction Form 
(Appendix 2) 
CLHIV 140 
Disclosure context Qualitative Interview Guide 
(Appendix 3) 
Parents/caregivers of 
CLHIV 
15 
Pre-test of Study tools Pre-test Questionnaire 
Data extraction form 
Interview Guide 
(Appendix 1, 2, 3) 
Parents/caregivers 3 
 TOTAL 298* 
* Not unique patients 
The study then sought to compare the group of disclosed children with non-disclosed children in terms 
of differences in health outcomes – CD4 count, number and frequency of opportunistic infections, viral 
load, and ART adherence during the three year study period. Below is the sequencing of the study 
components: 
Step 1: A recruitment letter with information on the study was read out by the doctor to each 
parent/caregiver of an eligible child at the end of their medical consultation.  
Step 2: Questionnaires were administered by the PI to 110 consented parents/caregivers of current 
pediatric ART patients.   
Step 3: Interview Guide was administered to 15 parent/caregivers of children who reported their child 
had been disclosed to during the administration of the study questionnaire (Step 2 above).  
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Step 4: For each completed questionnaire, information on patient’s CD4 count, treatment adherence, 
viral load, WHO staging and opportunistic infections was extracted from the patient’s paper charts or 
electronic records, using a data extraction form.  
Definition of key terms and variables 
Children living with HIV:  For this study, this was limited to children ≥ 6 years enrolled in the pediatric 
ART program at UATH. Enrollment for ART was deemed sufficient evidence of positive HIV sero-status. 
Pediatric disclosure: Defined as informing the child that s/he had HIV, regardless of whether it was 
intentional or accidental.  
Disclosure status: Children were categorized as disclosed or non-disclosed depending on whether they 
knew of their HIV positive status or not – as reported by the parent/caregiver. Information on disclosure 
status was gathered through the questionnaire that was administered to parents/ caregivers. A “Yes” 
response by the parent/caregiver to any of the questions: (1) Does child know s/he has HIV?; (2) Does 
child know s/he comes to clinic for HIV care?; (3) Does child know that the name of his/her sickness is 
HIV?; or (4) Does child know that s/he is taking medicine for HIV? was taken as evidence of child’s 
disclosure, while a “No” was considered non-disclosure [4]. 
Parent/caregiver: Defined as an adult aged 18 years and over who was responsible for the day-to-day 
care of the minor (pediatric ART patient), including biological parents identified through eligibility 
screening by health care providers at the study site. 
CD4 decline: CD4 count (or CD4% if child is less than 5 years of age) is a measure of the body’s immune 
system response to HIV, with higher CD4 values suggesting a stronger immune response. A CD4 count 
taken before or within the first six months of ART initiation were defined as the baseline CD4 count.  
Changes in subsequent CD4 were measured against this baseline to determine if CD4 count had 
declined. In the case of untreated HIV infection CD4 cell count may decline, but a rebound may be 
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observed with good adherence to ART. Therefore, CD4 measurement is important because it is a 
practical sign of both disease progression and adherence to ART [2]. Since CD4 count is expected to 
remain stable, or increase when on ART, when a decline in CD4 is observed, it is often an indication of 
poor adherence. A CD4 count of ≥500 cells/ml is associated with good viral suppression, while a CD4 
count of 200 to 499 cells/ml is considered moderate viral suppression. Counts below 200 cells/ml are 
considered severe immune suppression. A minimum of two valid CD4 counts taken during the three year 
study period were required for inclusion in the analysis. CD4 decline was considered to have occurred if, 
for any two consecutive CD4 counts (or between baseline and subsequent CD4 count), the later CD4 
count was lower by a value of up to 50 cells/ml and crossed between the various thresholds (severe, 
moderate or no immune suppression) [5].  The requirement for the difference in CD4 value of 50 
cells/ml was to ensure that the decline was clinically significant [5]. Data on CD4 count were extracted 
from the patient’s paper or electronic medical records. CD4 counts were measured every three months 
at UATH. 
Frequency of opportunistic infections:  Data on incidents of opportunistic infections in pediatric ART 
patients were limited to those available in patient paper or electronic medical records.  Opportunistic 
infections of interest were limited to serious ones (WHO stage 3 and 4) such as tuberculosis, esophageal 
candidiasis, and cryptococcal meningitis. Opportunistic infections that had occurred or were treated 
outside of the ART clinic and/or not recorded in the patient treatment records were not included in the 
analyses. The study sought to compare the average number of times patients received treatment to 
manage opportunistic infections at the study site (proxy for number of episodes) for disclosed versus 
non-disclosed children.  
ART (Treatment) adherence: Treatment adherence meant not missing doses of prescribed medication. 
Patient medical records on ART adherence are updated during patient visits based on patient reported 
missed doses. Antiretroviral drugs (ARV) are dispensed to patients on a monthly basis at the 
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commencement of ART. Thereafter, ARV is dispensed on a two-monthly basis. Treatment adherence is 
measured in percent, with a minimum of 95% adherence (i.e. not missing more than three doses per 
month or one dose in ten days, of a twice daily regimen) required to prevent drug resistance [6]. The 
average of all adherence data for the three year study period that was available in the paper or 
electronic medical records were calculated for each patient.  Non-adherence was therefore missing 
doses in the past 30 days [4]. Average adherence rates less than 95% were considered non-adherence. 
Average adherence ≥95% was considered adherence.  
Viral Load: Viral load is a measure of viral burden in the blood. The more HIV reproduces in the body, 
the higher the viral load. Viral load is measured as number of copies of viral particle per milliliter of 
blood. It is an objective assessment of how the body is fighting HIV, and of the efficacy of, and 
adherence to, HIV treatment. Viral load together with CD4 count provide a good picture of how the 
body is fighting HIV. Monitoring CD4 counts and viral loads during treatment helps the doctor assess 
how well the patient responds to their prescribed treatment. Low viral load indicates successful 
adherence to treatment. Under optimal conditions, administration of ART should lead to rapid and 
sustained suppression of viral load. Usually by week 24 following initiation of treatment, a patient’s viral 
load should be at the least < 400 copies/ml. The ideal is sustained viral suppression at 50 copies/ml for 
as long as possible to halt, prevent or delay disease progression [2]. Ideally, in the treatment-naive 
patient viral suppression to <50 copies/ml should be achieved and sustained by 16-24 weeks following 
commencement of ART. Therefore, virologic failure is described as viral load not suppressed to 
undetectable levels (<400 copies/ml) after 6 months on ART; and viral load not suppressed to 
undetectable levels (<50 copies/ml) after 12 months on ART.  Viral load measurements were taken every 
six months for each patient at UATH. 
For the purposes of this study, therefore, patients on treatment for up to six months, but less 
than 12 months, were expected to have viral load suppressed to undetectable levels (<400 copies/ml), 
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to be considered adherent. Patients on treatment for ≥ 12 months were expected to have viral load 
suppressed to undetectable levels (<50 copies/ml) to be considered adherent. Patients with viral load 
measures greater than these values were considered non-adherent. Average values for disclosed 
children were then compared with those for non-disclosed children. 
Subject inclusion and exclusion criteria 
Children who met all the following criteria were eligible for enrollment in the study, if: 
 Child was confirmed with HIV-infection in accordance with the Nigerian National Testing 
algorithm [2].  
 Child was ≥  6 years of age and was receiving HIV care and medication at the pediatric ART clinic 
at UATH 
 Child was currently prescribed antiretroviral medications for treatment of HIV disease based 
upon relevant Nigerian Guidelines [2], regardless of time of enrollment, or adherence to 
regimen, with no planned treatment interruptions. However, patient records had to provide at 
least two CD4 readings for the patient to be included in the study (estimated to be at least a 
minimum of three months).  
 Child was with at least one biological parent or caregiver at the study site, who was able to act 
as the child’s agent under Nigerian law and local practice, and who provided informed consent. 
Children and their parent/caregivers were not eligible to enroll in the study if: 
 Child shared the same parent/caregiver or lived in the same household as an already-enrolled 
child 
 Parent/caregiver of child did not speak or understand English, Hausa, Igbo, Yoruba, or Pidgin 
English  
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 Child had severe developmental impairment that would impact understanding of disclosure of 
status  
Study Limitations:  Disclosure information was based solely on information provided by 
parents/caregivers. This was subject to recall bias, as respondents may not recall actual date/period of 
disclosure. This ultimately affected categorization of pediatric patients as disclosed or non-disclosed. A 
targeted convenience sample of participants was taken rather than a random sample. Only participants 
who “volunteered and agreed” to participate in the study were included. This self-selected sample may 
be different from the rest of patients, and thus may not be fully representative of pediatric patients at 
the study site. Only opportunistic infections managed at the study site and entered in the medical charts 
were included in the study. This may not fully represent all episodes of opportunistic infection as some 
may be self-managed, or managed elsewhere. Finally, the current study design could allow for only 
correlations between variables to be made, and no causal inferences. 
IRB AND ETHICAL CONSIDERATIONS 
Study on vulnerable population: Although this study was on children living with HIV, the PI had no 
contact/direct interactions with these children. Only the parents/caregivers were interviewed. Children 
were also not in the room during the interviews with their parents/caregivers, to prevent any accidental 
disclosure of their HIV status. 
Psychological risk of accidental status disclosure to child participants: Children may cry, feel sad or be 
depressed when they learn they have HIV. Measures were taken to ensure there was no inadvertent 
disclosure of HIV status to children who did not know their status. This included not having children in 
the room during interviews with parents/caregivers, not mentioning HIV when parents/caregivers were 
informed about the study after their medical consultation with the doctor, as the children were with 
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them in the consultation room; and not assenting/consenting the children for the study. No child 
inadvertently learned about their HIV status in the course of the study. 
Privacy and confidentiality: To ensure confidentiality of participation, all instruments and forms were 
coded with a unique subject identifier that rendered the data anonymous to persons outside the study. 
Patient names were not used on any study instrument. Data were kept in a locked cabinet. Research 
records were kept confidential to the level allowed by law. Records with identifying information, such as 
consent forms, were stored separately from survey information.  
Informed consent: The PI obtained written consent from parents/caregivers of pediatric ART patients at 
enrollment. Consent and enrollment took place at the UATH after permission had been received from 
the potential participant to hear about the study. All study procedures were described in detail such that 
the participant was fully informed of their requirements while in the study.  During this consent process, 
the study subjects were reminded they were completely free to choose to take part in the research or 
not, and that their decision would not affect their care at the clinic. Potential study subject agreed or 
declined to participate in the study. Those who consented to participate in the study were enrolled. The 
consent form was reviewed orally by the PI and the participant was invited to ask detailed questions 
about the study. Study participants were consented and interviewed in their language of choice. Most 
parents/caregivers at the clinic spoke English or Pidgin English. Only a few parents/caregivers did not 
speak or understand English or Pidgin English, and spoke only Hausa. In these few cases, where the 
subject was non-English speaking, the consent form was read out in the local language (Hausa) via an 
interpreter, who was a health care worker at the clinic. Such interviews were also done in the local 
language with the assistance of an interpreter who is fluent in the written and spoken local language. 
Since there are many Nigerian languages, the questionnaire was not translated. All participants were 
informed that the information they provided through interviews was confidential (i.e., not shared with 
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anyone outside of the research team) and voluntary (i.e., they were not obliged to answer any 
question). Interviewees were told that they were free to take breaks and/or terminate the interview at 
any time.  
Duration and participant time commitment: This study lasted for seven months (February – August 
2015), which included time for both data collection and analyses. Parent/caregiver surveys were 
completed via a one-time visit with no subsequent contact following the initial contact. Each contact 
time with the parent/caregiver lasted approximately 20 – 25 minutes, including time for consent for the 
questionnaire, and an additional 20 – 25 minutes for the 15 parents/caregivers of disclosed children 
selected for the qualitative component of the study. Both study instruments were administered at the 
same one-time contact. Parents/caregivers and their children did not receive any incentives or 
payments for their participation in the study, beyond verbal gratitude expressed by the PI for their 
participation. 
Linking questionnaire to patient medical records: The questionnaire and patient extraction form 
received a unique identifier for each child. No names appeared on these two instruments. After each 
interview with a parent/caregiver, the patient’s medical file number and questionnaire unique identifier 
were noted in a separate notebook, which was stored in a safe place and separately from completed 
questionnaires and data extraction forms. Information in the notebook enabled the PI to retrieve 
patient medical paper or electronic records in order to retrieve the necessary information on the patient 
extraction form. 
Data security considerations: The survey was mostly paper-based, and required only minimal additional 
electronic data. There was no personally identifiable information in/on any of the study instruments. 
The PI used a notebook to note down patients' chart numbers, in order to later retrieve patient 
information from their charts. This notebook was the only medium that contained identifiable 
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information (I.e. medical record number).  The PI stored the notebook separately and securely from the 
study instruments, under lock and key when not in use. As soon as the PI retrieved the needed patient 
information (which did not include any identifiable information) the notebook will be destroyed. No 
identifiable information was stored electronically. 
DATA ANALYSES 
Quantitative data: A data dictionary was constructed for the questions in the survey questionnaire and 
the applicable values. Questions in the survey questionnaire were also pre-coded before administration 
to facilitate easy data entry. Data were analyzed using SPSS statistics version 20 and STATA version 12 
software packages. Descriptive statistics sought to determine the distribution of key variables within the 
sample and respondent characteristics, such as numbers of respondents by gender, socio-demographic 
characteristics of parents/caregivers, age of patients, and disclosure status, age at disclosure, who 
disclosed, and setting of disclosure. Means, medians, ranges, percentages and standard deviations were 
calculated as appropriate. Some data grouping was done for patient age (6 – 9 years, 10 – 14 years, > 15 
years), age at disclosure, and patient family socio-demographic data. The second level of analyses 
involved bivariate analyses that compared the relationship between observed health outcomes, namely, 
ART adherence, for disclosed and non-disclosed children, and if this difference was statistically 
significant. Chi square tests were calculated to test any associations between disclosure status 
(categorical variable) and other categorical variables.The next level of analyses used multivariate logistic 
regression and multinomial logistic regression models to determine the relationship between disclosure 
and socio-demographic characteristics of the patients, and the parents/caregivers, in order to determine 
the predictors of disclosure. Explanatory variables for each model were retained based on statistical 
significance, and conceptual relevance. Odds ratios with 95% confidence intervals were estimated from 
each explanatory model. Statistical significance was set at p value ≤ 0.05. 
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Qualitative data: The PI typed up the handwritten notes from the interview with each parent/caregiver. 
This was followed by a line-by-line analysis of the notes, in order to sort and code information from 
these interviews. Responses to each question were then gathered together and reviewed to check for 
any emerging themes. Ideas were sorted into similar themes, and codes were developed based on the 
themes. The emerging themes were then aggregated to provide a fuller picture of why disclosure takes 
place, how, when and by whom.  
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CHAPTER 4 
PATTERNS, PREVALENCE AND PREDICTORS OF PEDIATRIC DISCLOSURE AMONG HIV-INFECTED 
NIGERIAN CHILDREN ON TREATMENT 
INTRODUCTION 
In 2014 there were 36.9 million people living with HIV globally [1]. Of these, 25.8 million lived in sub 
Saharan Africa (SSA), including 2.3 million children (or 90% of all infected children 0 -14 years in the 
world) [1]. This implies that SSA continues to bear the largest burden of the global HIV epidemic. There 
has been considerable progress in preventing perinatally transmitted new infections in children through 
prevention of mother to child transmission programs. However, new infections in children 0- 14 years 
have remained largely unchanged in Nigeria. There were 220,000 new HIV infections in children 0-14 
years globally in 2014. Of these, 190,000 were in SSA [1], and Nigeria contributed 60,000 of these in 
2012 [2]. With 430,000 children 0-14 years living with HIV in Nigeria in 2014, the country accounts for 
almost one-fifth of all children living with HIV (CLHIV) in the world [3].  
These children are growing into adolescence (10 – 19 years) - a period of life involving significant 
physical, physiological and psychological changes that mark the transition to adulthood [3]. For CLHIV, 
they bear the added challenge of a life-long illness. Adolescence is also a period marked with 
experimentation, and for many adolescents, this phase of their lives will mark their sexual debut. It 
becomes important, therefore, that CLHIV know their HIV status – not only to protect themselves from 
reinfection, but also to protect their sexual partners. 
In 2011 WHO published the Guideline on HIV disclosure counselling for children up to 12 years of 
age, which recommends that children of school age (6 – 12 years) should be told their HIV positive 
status, and younger children should be told their status incrementally to accommodate their cognitive 
51 
 
 
skills and emotional maturity, in preparation for full disclosure [4]. The Nigeria Integrated National 
Guidelines for HIV Prevention, Treatment and Care highlights the importance of HIV disclosure to 
children [5]. It recommends the following steps for pediatric HIV disclosure: 
 Evaluate the child and family for readiness-including child’s age and maturity. Five to seven 
years are earliest recommended ages for disclosure, and all [children] should be disclosed by 
age 12 years.  
 Ascertain a child’s and caregiver’s understanding of HIV infection  
 Explain the benefits of early awareness of HIV infection to the child and caregiver/family 
 Provide ongoing psychosocial support. 
However, a recent study conducted in Nigeria showed only 13.5% disclosure rate [6]. Other recent 
studies on SSA have similarly reported low disclosure rates - 21% (Ghana), 17.4% and 39.5% (Ethiopia), 
19% and 26% (Kenya), and 32.6% (Cote d’Ivoire) [7-12].  
Factors that influence pediatric disclosure include child’s age and cognitive development, 
concerns about antiretroviral treatment (ART) adherence, imminent onset of sexual activity, and the 
need to protect others from infection. Benefits of pediatric disclosure include improved adherence to 
ART, and psychosocial well-being and mental health. Despite these benefits of disclosure, nondisclosure 
remains high because disclosure carries with it a negative exposure due to the association of HIV 
positive status and sex (promiscuity). Disclosure of HIV status to children living with HIV, or to partners, 
remains “navigation in a moral field” [13]. Therefore to protect the family name and one’s reputation, 
and avoid rejection and discrimination many choose not to disclose HIV status to children. Clearly, 
therefore, there is a need to understand the factors that promote or hinder pediatric HIV disclosure. 
This study, therefore, sought to determine the following in Nigerian children on ART: 
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1. The rate and nature of HIV status disclosure, and identify the main agent (family, healthcare 
worker, religious leader, school staff) of disclosure to these children 
2. The age at  HIV disclosure to children who have been disclosed to 
3. Locally pertinent barriers to, and facilitators of disclosure among disclosed and non-disclosed 
children 
4. Associations between disclosure, and health outcomes, namely: CD4 count, opportunistic 
infections, adherence to ART, and viral load. 
METHODS 
Study setting 
This study was conducted at the pediatric antiretroviral treatment (ART) clinic of the University of Abuja 
Teaching Hospital (UATH) in the Federal Capital Territory Abuja, Nigeria between February and July 
2015. This ART program was supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR) 
through the AIDS Care and Treatment in Nigeria (ACTION) program of the Institute of Human Virology 
Nigeria (IHVN). At the time of the study, a total of 401 children were currently receiving ART at the clinic. 
Of these, 35 (8.7%) were 0 – 5 years; 177 (44.1%) were 6 – 9 years; 139 (34.7%) were 10 – 14 years; and 
50 (12.5%) were ≥ 15 years.  
The paediatric clinic runs an “adolescent clinic” for older children once every month. During this 
clinic, nurses and adherence counsellors provide health talks to the older children and their parents, 
before they meet with the doctor for consultation. Some of these older children come unaccompanied 
to the clinic for their visits. The adherence counsellors also assess patient adherence, and provide 
counselling, as part of each patient’s visit to the clinic for consultation. Clinic staff (doctor, nurses and 
counsellors) also assist parents/caregivers with status disclosure to the children when necessary. 
However, there is no set pattern or procedure for how disclosure takes place.  
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Study participants, recruitment and design 
Study participants were CLHIV ≥ 6 years currently prescribed antiretroviral medications for treatment of 
HIV disease based upon relevant Nigerian Guidelines [14], regardless of time of enrollment, or 
adherence to regimen, with no planned treatment interruptions at the study site. Parents/caregivers of 
every eligible pediatric ART patient who visited the clinic for their regular consultation were invited to 
participate in the study. Parents/caregivers who agreed to participate in the study were consented by 
the Principal Investigator (PI) and interviewed, using a semi-structured questionnaire. The questionnaire 
sought, among other things, information on child’s disclosure status. If child was disclosed, the 
questionnaire also asked for age at disclosure, who disclosed the child’s status, where status disclosure 
took place, and reasons for disclosure. For parents/caregivers who had not disclosed to their children, 
the reasons for nondisclosure and concerns were obtained. The questionnaire also captured socio-
demographic data about the caregiver and the child, including relationship of respondent to child (i.e. if 
biological parent or other relative), and other characteristics of the family.  The administration of each 
questionnaire lasted about 20 - 25 minutes (including consent time). The interviews were conducted in 
the absence of the children to prevent accidental disclosure. Questionnaires were administered in 
English, Pidgin English, or Hausa through an interpreter. The PI continued with participant recruitment 
until end June 2015 when 110 participants had been recruited and interviewed. 
For each completed questionnaire, secondary data on CD4 count, opportunistic infections, WHO 
staging, viral load, and treatment adherence were later extracted from patient’s paper charts (and 
where these were missing, from the electronic medical records) for all 110 children, using a data 
extraction form (Appendix 2). Extracted data spanned the period 2013 to 2015. Other extracted data 
included patient age, date ART was started, and ART regimen. The data extraction process did not 
involve any direct contact with the children or their parents/caregivers.  
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Definition of key terms and variables 
Children living with HIV:  For this study, this was limited to children ≥ 6 years enrolled in the pediatric 
ART program at UATH, Abuja Nigeria. Enrollment for ART was deemed sufficient evidence of positive HIV 
serostatus. 
Pediatric disclosure: Defined as informing the child that s/he had HIV.  
Disclosure status: Children were categorized as disclosed or non-disclosed depending on whether they 
knew of their HIV positive status or not – as reported by the parent/caregiver. Information on disclosure 
status was gathered through the questionnaire that was administered to parents/caregivers. A “Yes” 
response by the parent/caregiver to any of the questions: (1) Does child know s/he has HIV?; (2) Does 
child know s/he comes to clinic for HIV care?; (3) Does child know that the name of his/her sickness is 
HIV?; or (4) Does child know that s/he is taking medicine for HIV? was taken as evidence of child’s 
disclosure, while a “No” was considered non-disclosure [11]. 
Parent/caregiver: Defined as an adult aged 18 years and over who was responsible for the day-to-day 
care of the minor (pediatric ART patient), including biological parents identified through eligibility 
screening by health care providers at the study site. 
Ethical considerations 
The study was approved by the Institutional Review Board of the University of North Carolina at Chapel 
Hill and the University of Abuja Teaching Hospital Medical Advisory Committee, Nigeria. 
Data analyses 
Data were analyzed using SPSS statistics version 20 and STATA version 12 software packages. Descriptive 
statistics sought to determine the distribution of key variables within the sample and respondent 
characteristics, such as numbers of respondents by gender, socio-demographic characteristics of 
parents/caregivers, age of patients, and disclosure status, age at disclosure, who disclosed, and setting 
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of disclosure. Means, medians, ranges, percentages and standard deviations were calculated as 
appropriate. Some data grouping was done for patient age (6 – 9 years, 10 – 14 years, > 15 years), age at 
disclosure, and patient family socio-demographic data. The second level of analyses involved bivariate 
analyses that compared the relationship between observed health outcomes, namely, ART adherence, 
for disclosed and non-disclosed children, and if this difference was statistically significant. Chi square 
tests were calculated to test any associations between disclosure status (categorical variable) and other 
categorical variables.The next level of analyses used multivariate logistic regression and multinomial 
logistic regression models to determine the relationship between disclosure and socio-demographic 
characteristics of the patients, and the parents/caregivers, in order to determine the predictors of 
disclosure. Explanatory variables for each model were retained based on statistical significance, and 
conceptual relevance. Odds ratios with 95% confidence intervals were estimated from each explanatory 
model. Statistical significance was set at p value ≤ 0.05. 
RESULTS 
Parent/caregiver characteristics 
A total of 110 questionnaires were administered in English (n=78), Pidgin English (n=25), and Hausa 
through an interpreter (n=7). Thirty-four (30.9%) of the respondents were male and 76 (69.1%) were 
female. Sixty-seven (60.9%) of respondents were child’s mother, and 26 (23.6%) were the father. The 
majority (n=105, 95.5%) were child’s primary caregiver. Most parents/caregivers had ever been to 
school. Only five respondents (4.5%) had never been to school. Table 4.1 shows other respondent 
characteristics. 
Table 4.1: Respondent characteristics (N=110) 
Respondent Characteristic n (%) 
Gender 
 Male 
 Female 
 
34 (30.9) 
76 (69.1) 
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Age 
 ≤ 19 years 
 20 – 29 years 
 30  – 39 years 
 40 – 49 years 
 50 – 59 years 
 ≥ 60 years 
 
1  (0.9) 
9 (8.2) 
39 (35.4) 
47 (42.8) 
10 (9.1) 
4 (3.6) 
Relationship to child 
 Mother 
 Father 
 Sibling 
 Uncle 
 Aunt 
 Grandparent 
 Other 
 
67 (60.9) 
26 (23.6) 
4 (3.6) 
3 (2.7) 
7 (6.4) 
1 (0.9) 
2 (1.8) 
Respondent is child’s caregiver 
 Yes 
 No 
 
105 (95.5) 
5 (4.5) 
Level of education 
 Primary school 
 Secondary school 
 Post-secondary/Higher 
 No education 
 
25 (22.7) 
39 (35.5) 
41 (37.3) 
5 (4.5) 
Tribe 
 Hausa/Fulani 
 Igbo 
 Yoruba 
 Gwari/Gbagi 
 Tiv 
 Idoma 
 Igala 
 Edo (Bini, Ishan, Akoko-Edo) 
 Others 
 
9 (8.2) 
16 (14.5) 
4 (3.6) 
15 (13.6) 
7 (6.4) 
4 (3.6) 
4 (3.6) 
13 (11.8) 
38 (34.5) 
Religion 
 Christian 
 Muslim/Islam 
 
82 (74.5) 
28 (25.5) 
 
Child characteristics 
There were 60 male (54.5%) and 50 female (45.5%) children (Table 4.2).  The mean age (SD) of the 
children was 10.15 (2.97) years, with a median (range) of 9.50 (6 – 18) years. All the children were in 
school: 6.4 % in kindergarten; 70.9% in primary school, 22.7% in secondary school. Fifty-five children 
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were 6 – 9 years; 45 were 10 – 14 years; and ten were 15 – 18 years. There was limited information on 
mode of transmission in the medical records or from information volunteered by respondents (n=27, 
24.5%). The questionnaire did not seek to elicit the mode of HIV transmission. However, some 
respondents gave this information in the course of the interview. Majority of the children were infected 
perinatally (n=24, 88.9%). Two children were infected through blood transfusion, and one child was 
infected from sexual assault. 
Table 4.2: Child characteristics (N=110) 
Child characteristics n (%) 
Gender 
 Male 
 Female 
 
60 (54.5) 
50 (45.5) 
Age (completed years) 
 6 – 9 years 
 10 – 14 years 
 15 – 18 years 
 
55 (50.0) 
45 (40.9) 
10 (9.1) 
Class 
 Kindergarten 
 Primary school 
 Secondary school 
 
7 (6.4) 
78 (70.9) 
25 (22.7) 
Tribe 
 Hausa/Fulani 
 Igbo 
 Yoruba 
 Gwari/Gbagi 
 Tiv 
 Idoma 
 Igala 
 Edo (Bini, Ishan, Akoko-Edo) 
 Others 
 
11 (10.0) 
15  (13.6) 
10 (9.1) 
14 (12.7) 
8 (7.3) 
3 (2.7) 
5 (4.5) 
12 (10.9) 
32 (29.1) 
Mode of HIV transmission 
 MTCT 
 Blood transfusion 
 Sexual transmission 
 Total 
 
24 (88.9) 
2 (7.4) 
1 (3.7) 
27 
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Prevalence of HIV Disclosure 
According to parents/caregivers’ accounts 34 (30.9%) of the children knew they were living with HIV, 
while 74 (67.3%) did not know the name of their sickness was HIV (Table 4.3). There was a statistically 
significant difference between 6-9 year olds and 10 – 18 year olds who were disclosed, with more of the 
latter knowing their status:  9.1% versus 52.7% (Pearson chi-square tests: X2 = 25.482, df=2, p=0.000). 
Three (30%) of the 10 children in the study aged ≥ 15 years had not been disclosed to. Two respondents 
could not tell if child knew or not. One of these respondents was a 37-year old mother and caregiver of a 
7-year old boy. The other respondent was a 20-year old aunt (and not caregiver) of an 8-year old boy. 
Table 4.3: Child’s knowledge of HIV status 
Child’s age/ 
Child’s knowledge of status, n (%) 
Disclosed Non-disclosed Don’t know Total 
6 -9 years 5 (9.1) 48 (87.3) 2 (3.6) 55 (100) 
10 – 18 years 29 (52.7) 26 (47.3) 0 (0.0) 55 (100) 
Total 34 (30.9) 74 (67.3) 2 (1.8) 110 (100) 
Chi-Square Tests Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 25.482 2 .000 
 
Disclosure characteristics 
Mean age (SD) at disclosure was 10.47 (2.62) years, with a median (range) of 10.00 (6 - 17) years and 
mode of 10 years. The most common reasons for disclosure were related to adherence issues – either to 
help prepare the child to take his/her medicines or that the child had refused to take his medicines  
Table 4.4: Reasons for disclosure of child’s status to child  
Reasons for disclosure n (%) 
To help child take medicine/child refused to take medicine 13 (39.4) 
Child was asking a lot of questions 9 (27.3)    
Child is now mature/old enough 3 (9.1) 
So child can protect him/herself 1 (3.0) 
Child was sexually assaulted 1 (3.0) 
Doctor said I should tell her 1 (3.0) 
Other reasons 5 (15.2) 
Total 33 
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(Table 4.4). This was followed by the child asking a lot of questions related to his/her health, frequent 
visits to the hospital, or why s/he was taking a lot of medicines even though s/he did not feel ill, or why 
s/he was the only child in the family taking medicines.  
Most parents/caregivers did not disclose because the child was considered too young (84.0%) or 
will not be able to keep a secret (10.7%) (Table 4.5). Among parents/caregivers who cited child being too 
young as a reason for non-disclosure, 11 further explained that as a result of child’s age, child will not be 
able to keep their positive sero-status a secret – not realising the import of a positive sero-status and 
the resultant stigma and discrimination that could ensue. Three respondents gave other reasons for 
non-disclosure: One 37-year old mother said she did not have any particular reason for not disclosing to 
her 12-year old daughter. A 35 -year old mother’s reason for not disclosing to her 15-year old son was 
that she did not know how the child would react to disclosure; and one 26-year old female respondent, 
who cares for her 16-year old brother, did not disclose because she felt the health care workers should 
be the ones to disclose. 
Table 4.5: Reasons for non-disclosure of child’s status to child 
Reasons for non-disclosure n (%) 
Child is too young 63 (84.0) 
Child will not be able to keep it a secret 8 (10.7) 
It will make child sad 1 (1.3) 
Other reasons 3 (4.0) 
Total 75 
Of the 34 disclosed children, 27 (79.4%) were disclosed at home by their parent(s)/caregiver. 
The rest were disclosed at the hospital. Of these, five were disclosed by the health care provider, while 
two were accidental disclosure: one child, an 11-year old boy, overheard the health care provider talking 
to his mother about his illness. The other child, an 8-year old boy, figured out his status because he used 
to sit in for the health talks his mother used to receive at the hospital. Both his parents were HIV-
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positive. The father insisted that neither he nor his wife had any talks with the boy about his HIV status. 
However, he said the boy “has always known” he was positive. 
Predictors of disclosure 
The next level of analyses used logistic regression models to determine the relationship between 
disclosure and socio-demographic characteristics of the children and the parents/caregivers, in order to 
determine the predictors of disclosure. This was a multivariate logistic regression of knowledge of status 
against the following variables: child’s gender (male, female), age (in completed years), class at school 
(kindergarten, primary or secondary), child’s tribe (Hausa/Fulani, Igbo, Yoruba, Gwari/Gbagyi, other) and 
Table 4.6: Multivariate logistic regression of HIV disclosure to child (n=108) 
------------------------------------------------------------------------------------------------------------------------------ 
Know status |       Odds Ratio     Std. Err.       z              P>|z|      [95% Conf. Interval] 
-------------+--------------------------------------------------------------------------------------------------------------------- 
Child’s gender  
Reference Male 
Female   2.93     2.03       1.55   0.121       .75   -  11.40 
Child’s age       1.69     .28      3.12     0.002      1.21    - 2.34 
Child’s school class  1.69     1.42      0.62     0.536      .32   - 8.79 
Child’s tribe  
Reference Hausa/Fulani, Kaduna 
Igbo       .00     .01      -1.46     0.145     .79e-07 -  8.496  
Yoruba     3.16     9.69       0.38     0.707      .01 - 1283.41 
Gwari/Gbagyi   2.01  3.96       0.35     0.723      .04  -  95.65  
Other  .03  .09  -1.12  0.265  .00 – 13.60 
    Respondent’s relationship to child 
  Reference Father  
Mother, Other .94     .62     -0.10     0.924      .26  - 3.42  
Respondent’s religion 
  Reference Christian     
Muslim/Islam    1.09      .79      0.12     0.908      .26   - 4.54  
Respondent’s language 1.20     .42       0.52     0.606      .60   - 2.38  
Respondent’s tribe 
Reference Hausa/Fulani, Kaduna 
Igbo      40.15     164.40     0.90     0.367      .01  -  122792 
Yoruba   .07      .25       -0.75    0.454       .00  -  69.24  
Gwari/Gbagyi  .34      .67       -0.54     0.586       .01  -  16.31 
Other  20.98  64.84  0.98  0.325  .05 – 8960.58  
Respondent’s Age    1.05      .03        1.76     0.079     .99    - 1.12  
----------------------------------------------------------------------------------------------------------------------------------- 
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respondent relationship to child (mother, father, sibling),  age, tribe (Hausa/Fulani, Igbo, Yoruba, 
Gwari/Gbagyi, other), language and religion (Christianity and Islam). There were three categories of 
children – children who knew their positive HIV status; children who did not know their HIV status; and a 
third category of children whose parents/ caregivers responded they did not know if the children knew 
their status. Since the number of children under the “Don’t know” category was only two, two sets of 
multivariate logistic regression analyses were run: First, with the “Don’t know” category dropped from 
the analysis (Table 4.6); and secondly with the “Don’t know” category coded together with the no  
Table 4.7: Multivariate logistic regression of HIV disclosure to child (n=110) 
------------------------------------------------------------------------------------------------------------------------------- 
    Know status  Odds Ratio Std. Err.   z  P>|z|   [95% Conf. Interval] 
-------------+------------------------------------------------------------------------------------------------------------------- 
Child’s gender 
Reference Male 
Female      2.94      2.04       1.55    0.121        .75   - 11.44 
Child’s age     1.70     .28       3.16    0.002      1.22 -  2.35 
Child’s class      1.67     1.41       0.61    0.543       .32   -  8.71 
Child’s tribe 
Reference Hausa/Fulani, Kaduna 
           Igbo       .00     .01      -1.46    0.146       4.40e-07   -  8.71 
           Yoruba  3.20    9.83       0.38    0.706       .01 -   1323.99 
Gwari/Gbagyi 2.01     3.97       0.35    0.725       .04  -   96.80 
Others  .03  .10  -1.12 0.264  .00 – 13.64 
Respondent’s relationship to child  
 Reference Father 
 Mother, others  .93     .61      -0.11    0.912      .25   -  3.40 
Respondent’s religion   
 Reference Christian 
 Muslim/Islam  1.10     .80       0.12    0.901      .26  -    4.58 
Respondent’s language   1.20      .42       0.52    0.601      .60  -   2.40 
Respondent’s tribe  
           Reference Hausa/Fulani, Kaduna 
Igbo     40.89     168.56      0.90    0.368      .01  -   131922.9 
           Yoruba     .07     .25      -0.75    0.453      .00   -  69.56 
           Gwari/Gbagyi  .34     .66      -0.55    0.581      .01  -   16.20 
 Others  21.17  65.65  0.98 0.325  .05 – 9229.53 
 Respondent’s age 1.06      .03       1.79    0.073       .99    - 1.12 
------------------------------------------------------------------------------------------------------------------------------------- 
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disclosure category (Table 4.7). In both cases, only child’s age was a statistically significant predictor of 
status disclosure (OR 1.69, p=0.002; 95% CI 1.21 – 2.34), and (OR 1.70, p=0.002, 95% CI 1.22 – 2.35) 
respectively. Other child characteristics (gender, class in school, tribe) and parent/caregiver 
characteristics (religion, relationship to child, tribe, language and age) were not statistically significant. 
Multinomial logistic regression was also done, as a test of sensitivity. This was also a logistic 
regression of knowledge of status against child’s gender (male, female), age (in completed years), class 
at school (kindergarten, primary or secondary), child’s tribe (Hausa/Fulani, Igbo, Yoruba, Gwari/Gbagyi, 
other) and respondent relationship to child (mother, father, sibling). The analyses also tested 
parent/caregiver  
Table 4.8: Multinomial logistic regression of HIV disclosure to child 
 Child’s knowledge of 
HIV status 
Coef. Std. Err. z P>z 95% Confidence 
Interval 
Yes       
 Child’s gender 0.38 0.54 0.7 0.481 -0.68 – 1.45 
 Child’s age 0.36 0.13 2.84 0.005 0.11 – 0.60 
 Child’s class in school 0.67 0.71 0.94 0.345 -0.72 – 2.06 
 Child’s tribe 0.07 0.27 0.26 0.793 -0.46 – 0.60 
 Parent/caregiver 
relationship to child 
0.45 0.58 0.77 0.439 -0.69 – 1.60 
 Parent/caregiver 
religion 
0.54 0.66 0.81 0.417 -0.76 – 1.84 
 Parent/caregiver 
level of education 
-0.07 0.34 -0.19 0.846 -0.73 – 0.60 
 Parent/caregiver 
tribe 
0.10 0.12 0.87 0.386 -0.13 – 0.33 
 Parent/caregiver age 0.05 0.03 1.66 0.098 -0.01 – 0.12 
 Constant -10.66 2.75 -3.88 0 -16.05 - -5.27 
       
No (Base outcome)      
       
Don’t know      
 Child’s gender 34.29 12178.34 0 0.998 -23834.82 – 
23903.40 
 Child’s age -32.65 6743.69 0 0.996 -13250.05 – 
13184.74 
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 Child’s class in school 184.18 34534.36 0.01 0.996 -67501.93 - 
67870.28 
 Child’s tribe 54.20 14224.29 0 0.997 -27824.89 - 
27933.29 
 Parent/caregiver 
relationship to child 
56.03 12196.57 0 0.996 -23848.81 - 
23960.86 
 Parent/caregiver 
religion 
-59.03 21074.66 0 0.998 -41364.61 - 
41246.55 
 Parent/caregiver 
level of education 
-93.29 12331.29 -0.01 0.994 -24262.18 - 
24075.59 
 Parent/caregiver 
tribe 
-23.44 8111.85 0 0.998 -15922.37 - 
15875.50 
 Parent/caregiver age -3.89 699.05 -0.01 0.996 -1374.00 - 
1366.22 
 Constant -70.62 114523.30 0 1 -224532.10 - 
224390.90 
N= 108 
characteristics, such as age, education (no school, primary, secondary, post-secondary/higher), and tribe 
(Hausa/Fulani, Igbo, Yoruba, Gwari/Gbagyi, other). Again, only child’s age (in completed years) was a 
statistically significant predictor of pediatric disclosure: coefficient = 0.36 (p value 0.005, CI 0.1-0.6) 
(Table 4.8). The study did not show any association between disclosure and other child characteristics, 
such as gender, class in school or tribe, nor any association with parent/caregiver religion, level of 
education, tribe or age. 
HIV disclosure and child’s physical (clinical) health outcomes 
Almost all the patients (n=90, 80%) had several self-reported adherence data in their paper medical 
records. However, only two of these 90 children were recorded as non-adherent (Table 4.9). Analysis of 
the relationship between disclosure and adherence using Pearson chi-square tests showed no 
statistically significant difference in adherence between disclosed and non-disclosed children (X2= 0.972, 
df=2, p=0.615). There were limited data on patient CD4 count, and hardly any data on viral load, and 
opportunistic infections in the patient paper or electronic medical records. One hundred patients had at 
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least one CD4 reading in their records. However, at least two readings were required to determine if 
there had been a CD4 decline, or not. Fifteen children had at least one viral load measure. Only four  
Table 4.9: Relationship between disclosure and adherence 
Disclosure status/ 
Adherence status, n (%) 
Adherent Non-adherent Total 
 
Disclosed 
 
27  
100.0 
30.0 
0  
0.0 
0.0 
27 
100.0 
30.0 
Non-disclosed 
 
59 
96.7 
65.6 
2 
3.3 
2.2 
61 
100.0 
67.8 
Don’t know 
 
2 
100.0 
2.2 
0 
0.0 
0.0 
2 
100.0 
2.2 
Total 88 
97.8 
2 
2.2 
90 
100.0 
Chi-Square Tests Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square .972 2 .615 
children were reported to have had an opportunistic infection (pulmonary tuberculosis). As such, this 
dissertation does not present any findings on association between disclosure and child’s CD4, viral load 
or opportunistic infections.  
DISCUSSION 
Disclosure prevalence from this study was 30.9 %, with more 10 – 18 year olds significantly knowing 
their status than 6-9 year olds: 52.9% versus 9.1% (X2 = 25.482, df=2, p=0.000). The overall disclosure 
prevalence of 30.9% was much higher than the 13.5% reported from another study in Nigeria [6], and 
other studies from SSA: 17.4 % in Ethiopia [8], 19% in Kenya [10], 21% in Ghana [7]; and 26% in Kenya 
[11]. But it was similar to the 39.5% reported in Ethiopia [9], and 32.6% in Cote d’Ivoire [12]. The mean 
age (SD) at disclosure from this study was 10.47 (2.61) years. It was higher than the 8.7 (2.2) years 
reported from the earlier cited Nigeria study, but similar to the Ethiopia study of 10.7 (2.3) years. One 
could speculate that the lower disclosure rates in some of the SSA studies could be because these 
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studies were conducted a while ago (mostly in 2008 and 2009), even though the studies were on 
children of comparable age (usually 5 – 16 years). Since then, access to ART has expanded, possibly 
leading to relatively higher disclosure rates.  
As in other studies in the SSA region, reasons for disclosure were related to child’s adherence to 
medication, as well as repeated questioning from child on their illness and/or medication [6], [7], [9], 
[10]. Parents/caregivers in this study cited child’s young age and, therefore, inability to fully understand 
the import of a positive HIV serostatus (84.0%), and child’s inability to keep a secret (10.7%), with the 
resultant fear of stigma and discrimination that may arise from revealing their status to others, as major 
reasons for not disclosing child’s status. This result was not different from what other studies in the 
region have reported. In Brown’s Nigeria study [6], 63.9% parents/caregivers reported child’s inability to 
understand; and 41% reported fear of disclosure to other children; and 33.7% cited fear of disclosure to 
family/friends, as reasons for non-disclosure. Kallem [7] also reported that over half of parents/ 
caregivers (29 of 56 parents/caregivers) who had not disclosed gave fear that child would tell others as a 
reason for non-disclosure; and 26 of 56 parents felt their children were too young to be informed of 
their status. The analysis of parents citing child’s young age as a reason for non-disclosure in this study 
uncovers two underlying factors. First, the child is too young and therefore will not understand the 
import of an HIV diagnosis, predicated on child’s cognitive ability. Second, the child is too young and will 
not be able to keep a secret, not appreciating that HIV status could invite negative reactions, will expose 
themselves to stigma and rejection from their fellow children or the adults around. Unlike other studies 
[6], parents/caregivers in this study did not cite fear of blaming parents as a reason for non-disclosure. 
In this study, child’s age was the only factor associated with disclosure. Multivariate logistic 
regression of child’s age and status disclosure showed a statistically significant association (OR 1.68, 
p=0.002, 95% CI 1.21 – 2.34) and (OR 1.70, p=0.002, 95% CI 1.22 – 2.35). Multinomial logistic regression 
also showed a similar statistically significant association between child’s age and status disclosure (p= 
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0.005). Other studies in SSA also reported a similar association. Kallem’s study in Ghana reported age of 
child was a significant predictor of disclosure (Wilcoxon rank sum test, p=0.01) [7]. In Ethiopia, Biadgilign 
reported that children 10 – 14 years were more likely to be disclosed than younger children [(aOR = 
0.11; 95% CI = 0.03–0.34) and (aOR = 0.19; 95% CI = 0.10–0.37, respectively)] [8]. Similarly, Vreeman 
reported that in Kenya older age (OR 1.49, 95% CI 1.35–1.63) was significantly associated with disclosure 
[11]. Another study from Kenya showed that disclosed children had a higher median age than those who 
were not (13 years versus 8 years; p < 0.001) [10]. In Cote d’Ivoire, Meless reported that disclosure 
increased significantly with age (> 18 years vs. 13 - 15 years; aOR (22.1; 95% CI: 5.2 - 93.5; p <0.0001). 
Unlike the Kenya study by John-Stewart [10], which reported an association between caregiver 
age and disclosure (40 vs. 35 years; p = 0.009), this study did not find any such association. This study 
also did not find any correlation between disclosure and child’s level of education or class, nor the 
parent/caregivers’ level of education. However, Kallem reported that disclosure was significantly 
associated with child’s level of education (Fisher’s exact test, P < 0.01) [7]. Biadgilign reported that 
children whose caregivers were educated up to primary level or higher were less likely to be disclosed 
compared to children whose caregivers were illiterate [8].  
This study did not show any relationship between child’s knowledge of his/her status and self-
reported adherence (X2= 0.972, df=2, p=0.615). However, Vreeman’s Kenya study showed mixed results, 
with children reporting more adherence than caregivers [11]. There continues to be a need for more 
objective and reliable measures of adherence, such as viral load, since self-reports may not be reliable. 
Incidentally, there were limited viral load data in patients’ medical files at UATH for analysis. Only 15 
patients had any viral load readings in their files, even though viral load measurements were supposed 
to be taken every six months.  
This study had several limitations. A targeted convenience sample of participants was taken 
rather than a random sample. Only participants who volunteered and agreed to participate in the study 
67 
 
 
were included. This self-selected sample may be different from the rest of the patients, and thus may 
not be fully representative of pediatric patients at the study site.  
Some older adolescents came unaccompanied for their consultations. They were, therefore, not 
interviewed as part of the study, since the study was designed to only interview parents/ caregivers and 
not the children themselves. It is possible that this group of older children were disclosed. Therefore, it 
is likely that the actual disclosure rate for this site could be higher than the 30.9% reported from this 
study.  
Finally, the current study design could only allow for correlations between variables to be made, 
and no causal inferences. 
CONCLUSION 
The HIV disclosure rate for CLHIV seen at UATH was low, similar to rates reported by other studies in 
SSA. Child’s age was the only predictor of HIV disclosure to the child. Child’s young age was the major 
reason given by parent/caregivers for not disclosing child’s positive HIV status to the child. 
Parents/caregivers who disclosed child’s status to child did so mostly for reasons related to child’s 
adherence to medication. The study did not find any association between disclosure and self-reported 
adherence. 
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CHAPTER 5  
THE CONTEXT AND PROCESS OF PEDIATRIC HIV DISCLOSURE 
INTRODUCTION 
Improved access to antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has meant that more 
children living with HIV (CLHIV) are growing into adulthood. With a 2013 population of 170 million 
people, Nigeria is Africa’s most populous country. In 2012 there were over 3.4 million people living with 
HIV in Nigeria, including an estimated 430,000 children under 15 years of age [1].   
The World Health Organisation (WHO) recommends pediatric disclosure, defined as disclosure 
of a child’s seropositive HIV status to the child or informing the child that s/he has HIV, to children of 
school age (6 – 12 years) [2]. However, despite the reported benefits of disclosure, many studies in SSA 
report low disclosure rates to children. A 2013 national survey of Nigerian adolescents aged 10 to 19 
years showed that >80% of adolescents did not know their HIV status, and up to 6% of parents of CLHIV 
admitted to not disclosing the children’s status [3]. Only 13 (13.5%) children in a Nigeria HIV Care 
program had been disclosed to [4].  Other recent studies in SSA also show low disclosure rates:  21% 
(Ghana), 17.4% and 39.5% (Ethiopia), 19% and 26% (Kenya), and 32.6% (Cote d’Ivoire) [5-10]. Given the 
high number of children living with HIV in Nigeria, the culture of non-disclosure to these children, 
especially as they approach sexual debut, is likely to have negative consequences. 
Many issues surround disclosure, such as: Who should disclose to the child – the parent or the 
health care worker? Where should disclosure take place – at home or the health facility? At what age 
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should the child be disclosed? How should disclosure take place – as a one-off discrete discussion or a 
gradual process consisting of several discussions over a period of time? [2]. 
Parents/caregivers of CLHIV often cite many reasons for not disclosing to their children. These 
include concerns around how the children would react, if told they were living with HIV [5] [7]; children’s 
young age, and therefore inability to understand the implications of an HIV diagnosis [4] [7]; and the 
fear of children being stigmatised in their communities if their positive HIV status were disclosed by the 
children to others in the community [7]. Many parents/caregivers also report they lack the skills to 
disclose to their children [11].  For parents/caregivers who disclose, their reasons for disclosure include 
repeated questioning by the children regarding their continuing taking of medications, the need to 
promote medication adherence, and the perception that the children were now mature enough to 
understand their HIV-positive diagnosis [4], [5], [12]. Where disclosure happens it is often unplanned, 
and does not take place in a systematic way. The process remains largely context dependent [12]. WHO 
has, therefore, provided some guidance on how country programs could address many of these issues, 
in order to increase disclosure to children [2]. 
This study on children who have been told they are living with HIV, therefore, sought to elicit 
the process and context of disclosure, the reasons for disclosure, who disclosed to the children, when 
and where disclosure took place, and other emerging themes. It is hoped this will contribute to the body 
of Nigeria-specific knowledge on pediatric HIV disclosure, and help shape the development of HIV 
disclosure guidance in Nigeria, and elsewhere in the SSA region. 
METHODS 
This qualitative study was nested in a larger study that also included a quantitative component. In this 
study, respondents who explained that they had disclosed to their children in the quantitative 
component were further interviewed by administering an interview guide (Appendix 3). 
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Setting 
The study was conducted at the pediatric clinic of the University of Abuja Teaching Hospital (UATH), 
Abuja, Nigeria. As at June 2015, there were 401 children receiving ART at this clinic. The Institute of 
Human Virology Nigeria (IHVN) supports the provision of ART services at the clinic, through its AIDS Care 
and Treatment in Nigeria (ACTION) program, with funding from the US President’s Emergency Plan for 
AIDS Relief (PEPFAR). IHVN is an indigenous nongovernmental organization, which until 2010 was 
affiliated with the University of Maryland Baltimore USA to implement the ACTION program. IHVN’s 
pediatric ART program started in 2006. As at January 2012 IHVN’s follow-on ACTIONPLUS pediatric ART 
program supported 36 health facilities in 18 of the 36 states in Nigeria and the FCT. IHVN sites provided 
ART to 89,509 persons, including 5,265 children (0- 14 years). 
Study design and participants 
In the course of the larger study, 34 parents/caregivers reported that their children knew of their 
positive HIV status during the administration of the study questionnaire. Of these, the interview guide 
was administered to 15 of them, to more fully elicit the process of disclosure to their children. The aim 
of the study was to determine the context of HIV disclosure to the child, in order to more fully 
understand how the disclosure process happened: how was the decision made to disclose to the child; 
what was the setting for disclosure; and what were the parents/caregivers concerns regarding 
disclosure. The interview also explored parent/caregiver perceptions of the effects of disclosure on the 
child, especially child’s emotional reaction to disclosure. The interview was designed to be 
conversational and used probes to elicit a description of the process, who disclosed to the child, where, 
when and how disclosure took place. The interviews also sought to clarify if the terms “HIV”, “AIDS” or 
any local term was specifically mentioned to the child during the disclosure process. For a child to be 
determined as disclosed, the term HIV or AIDS or a local equivalent term must have been used in 
discussion with the child about the child’s health by parent/caregiver, or healthcare worker [12].  
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Data collection and analysis 
Data collection took place between February and June 2015. Data collection continued until 15 
parents/caregivers had been interviewed. The principal investigator (PI) took notes by hand during the 
interviews. No parent/caregiver consented to being audiotaped during the interviews. Thereafter, the PI 
typed up the notes from the interview with each parent/caregiver. This was followed by a line-by-line 
analysis of the notes, in order to sort and code information from these interviews according to 
disclosure themes, such as, reasons for disclosure, who disclosed, where, when and how disclosure took 
place, and other emerging themes.  
Ethics 
The Institutional Review Boards at the University of North Carolina at Chapel Hill USA, and the University 
of Abuja Teaching Hospital approved this research.  
 
RESULTS 
Process of disclosure 
Descriptions provided by parents/caregivers of the disclosure process suggest that this was usually a 
discrete, one-off event that was unplanned. There was often no scheduled discussion to disclose to the 
child.  
One morning we were about to come to hospital. Then I told him about the reason why 
we were coming. I asked him first of all, then I told him. Do you know the reason for 
your [coming to hospital?] I asked him what is called HIV? He said No [he didn’t know]. 
That’s what the doctor says is your sickness. It is what we are going for. 
There was a day he kept asking me. After school we will discuss topic of the drugs. So 
when they were teaching them about drugs in Social Studies [in school], he asked for 
HIV, what it means. I now explained the drugs he is taking is ART, to kill HIV in the 
system. 
Disclosure was, also sometimes triggered by an event, for instance, exasperation with child for refusing 
to take their medicine.  
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It was in the morning. It is not because I planned it. But because he refused to take his 
medicine…That’s why I told him that the sickness will kill him.  
Even when it was the health care worker who disclosed, there did not appear to be any prior 
preparation of the parent/caregiver or child. There was also limited follow on disclosure sessions. 
However, some parents mentioned they reinforced the information health care workers had provided, 
or vice versa. 
When I came for appointment they asked me if I had told her. They told me why now? I 
don’t know how to explain it. It was that very day they told him. It was that very day. 
In one instance, where the child probably got infected via sexual assault/transmission, the disclosure 
process was also unplanned and a discrete event. 
Doctor called and informed me. So I asked her. I don’t have it. So how comes you have 
it. That’s when she opened up and told me that a man came across her. 
On the one occasion when it appeared disclosure was planned, it took place the same day. There were 
no subsequent, deliberate, follow-on discussions on disclosure. It was usually that one conversation. 
It was at midnight. I did not want anybody to hear me. I’d been telling her that day to 
remind me [that there is something I wanted to tell her]. She kept reminding me. Then I 
told her. Do you know why we are forcing you to take medicine? It’s because you have 
HIV. Don’t let anybody know. 
The conversation about the child’s HIV status often took place in private between the child and 
parent(s). Other siblings or persons were usually not around. 
It was after evening devotion [prayers]. I asked the other children to go to bed. Then it 
was just me and the mother. Then I told him. 
 
It was me and my wife. I decided to tell him at that time. There was a seminar here [the 
hospital]. He was invited. I wanted him to know before then. 
There were a number of families at the hospital where several children were living with HIV. In such 
cases, parents/caregivers would usually disclose to the children at the same time, rather than 
individually. 
It was at night in the house. The step mom was not around. It was private time. I told 
him and his brother at the same time.  
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Table 5.1 Characteristics of caregivers and disclosed children  
Case # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Parent/caregiver characteristics 
Age 
(years) 
32  47 42 50 55 40 48 30 45 38 63 45 37 62 60 
Gender 
 
Female Male Male Male Male Female Female Female Male Female Male Female Female Male Female 
Relation-
ship to 
child 
 
Mother Father Father Father Father Mother Mother Mother Father Mother Father Mother Mother Father Aunt 
HIV status 
 
Positive Positive Negative NA Negative Positive Positive NA Negative Positive NA Negative NA Positive Positive 
Child characteristics 
Gender 
 
Female Male Male Female Female Female Female Male Male Female Male Female Male Male Male 
Age at 
interview 
(years) 
 
11  10  13  16 11 9 13 11 18 12 16 15 9 13 11 
Age at 
diagnosis 
(years) 
 
6 mo 3.5 11 7 9 8 mo 12 6 3 10 13 8 2 5 8 mo 
Age at 
disclosure 
(years) 
 
11  4 12 14 10 7 12 7 15 12 13 13 8 13 10 
 NA = Not available  mo = months 
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Reasons for disclosure 
By far the most common reason parents/caregivers gave for disclosure was related to the children 
taking their drugs. Children complained of being tired of constantly taking medicines, even when well, 
and were refusing to take their drugs. Another related reason, as one parent put it, was that parents felt 
the children needed to know why they were taking drugs, especially before the children started taking 
prescribed medicines, in order to prepare them. Yet other parents felt children needed to take more 
responsibility for taking their drugs, even when their parents were not around. These parents felt 
disclosure would ensure such responsibility for medication adherence. 
They are asking me they are tired of taking the drugs. So I had to tell them. 
 
So he can take his medicines because sometimes he refuses to take his medicine. That’s 
why I told him that the sickness will kill him. Since I told him he became consistent in 
taking the drugs. 
 
I want her to take her medicine… let her know her status…let her know her condition so 
she can take care of herself. 
 
I prepare him to take the medicine properly, so he can take his drugs even when I am 
not around. I am not always around when he takes the drug. 
 
Because when she comes here [the hospital] she will be given drugs. So she should 
know why she should be given the drugs.  
 
Some parents also spoke of feeling the children were now cognitively developed to understand what 
being diagnosed with HIV meant. The parents felt the children were now mature, and ought to know 
their status.  For other parents, children being mature meant they could now keep their status a secret, 
if told, without disclosing it to others.  
At that age I didn’t tell him. But when I know he can understand I told him. 
 
By now she’s matured. By 12 years I can explain a little bit to her. She’s having maturity 
now.  
I hide it from him so he will not expose himself. But as I see he is getting matured I 
decided to speak with him. He is going to age of reason, wanting to understand reason 
for his drugs. I was waiting for when he is able to understand. 
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Knowing their status would also enable the children to be discreet with their ARV drugs, and not 
inadvertently expose their status to others.  
I wanted him to know before other people will embarrass him, kind of. It is possible 
somebody will see him with the drugs and begin to ask him questions.  
 
One parent described her dismay that her son would take his box of pills outside the house to show his 
playmates. Since the child did not understand what illness the medicines were meant for. This parent 
had experienced discrimination from her neighbours at home and in church when they learnt she was 
living with HIV. She did not want her son to go through the same experience with his playmates. 
Dis medicine no be everybody for carry am go outside. You know say de medicine e go 
dey carry am show people. Em say e no know. Now e dey take medicine for inside house 
 
One parent disclosed only because the doctor had asked him to. 
If doctors had not asked me to tell her I will not have told. 
Person who disclosed, and where 
Disclosure happened either at home or in hospital. Majority of the children were disclosed to at home 
by their parents/caregivers (Table 5.2). This was either the mother, father or both parents. Parents 
chose to be the ones to disclose for a variety of reasons – either because they felt it was their duty, and 
therefore they should be responsible for disclosing to the child; or they felt it would be good for the 
children if they disclosed. In other cases, they simply disclosed because at the time of disclosure, it was 
the parent the child asked the reason for taking drugs. 
I felt it was my duty to tell him  
It is good for me to tell them. No need for somebody else to tell them 
At that time, it was me she asked. That’s why I told her.  
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Two children were disclosed to at the hospital by a health care worker – the doctor, in one instance, and 
by the nurse (chief matron) at the pediatric clinic. One 13-year old girl was diagnosed with HIV while on 
admission in hospital. The doctor then disclosed her status to her. One parent felt he did not have the 
skills to disclose to his child so requested for the health care worker’s help.  
For me to tell her I may not express myself the way she can know it better. That’s why I 
told doctor they are the people who can explain it better. 
 
There were no reported cases of disclosure by clergy in church or the school environment, or elsewhere. 
Children’s reaction to disclosure 
Children’s immediate reactions ranged from no reaction, calmness, and being quiet, as reported by four 
parents, to sadness in two children, shock or mild shock for two children, anger by one child, and crying 
by two children. In one case, both parents and the child cried at the time of the disclosure.  
  There was no reaction – no tears, nothing. 
He’s still junior. He didn’t feel anything. 
He became cold. He listened to me. When I finished, he remained quiet. He was 
reflecting on it. We lost two of his sisters. I had to tell him it is the reason [i.e. his sisters 
died from AIDS] 
It’s like he knew already what I was saying. He was not terribly shocked. 
  She was shocked. 
  We all shed tears, wondering how this sickness came into being 
The parents were, however, quick to add that the children’s reactions were only immediate, and quickly 
passed. 
  She became sad somehow, [but] only that day. 
  She was very sad. But now she does not talk about it. 
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Table 5.2 Characteristics of disclosure 
Case # 
 
Who 
disclosed 
Where When Others present 
during disclosure 
Reasons for disclosure Child’s reaction to disclosure 
1 Mother Home At night No Child refused to take his 
medicines 
No reaction 
2 Accidental 
disclosure 
Hospital During health 
talks with 
mother at the 
clinic 
Mother Not applicable Not available 
3 Father Home At night, after 
evening 
prayers 
Mother So child can take his medicines 
even when his father was not 
around 
Cry 
4 Father Home In the morning No Child was asking when she 
would stop taking her medicines 
No reaction 
5 Health care 
worker 
Hospital During regular 
clinic visit 
Father Doctor asked that the child be 
disclosed 
Not available 
6 Mother Home  Sister who was 
also HIV-positive 
Child was complaining that she 
was tired of taking medicines 
Shock 
7 Health care 
worker 
Hospital Child was 
admitted in 
hospital 
Mother and sister 
who were both also 
HIV-positive 
So they will know how to live 
their lives 
No reaction (probably because 
child was too sick). But the other 
sibling cried. 
8 Mother Home morning No Child refuses to take his 
medicines 
No reaction 
9 Father Home At night Brother who was 
also HIV-positive. 
Step mother was 
not around 
Child was now mature “He became cold” 
10 Mother Home Not available Father 
 
She is mature now “She was very sad” 
11 Father Home In the morning 
as they were 
about to come 
to the hospital 
Not available So child can know why he is 
taking medicines 
“He is still junior. He did not feel 
anything” 
12 Mother Home Not available Not available Child was complaining she was 
tired of taking medicines 
Anger (child was infected 
through blood transfusion) 
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13 Mother Home When child 
came back 
from school 
Not available Child was asking questions “He was somehow” 
14 Father Home Not available Not available So child can be discreet with his 
medicines 
“He was not terribly shocked. It 
was as if he knew already” 
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In one instance, an older sibling (not living with HIV) overheard her mother (who is also HIV-positive) 
disclosing to the younger sister who is living with HIV. She started crying, perhaps thinking her mother 
would soon die.  
The senior girl [older daughter] heard and started crying. I had to ask her, “Did you see 
anybody dying? Do I look like I am going to die? I am not going to die. See, I am 
healthy.” 
 
Conversations with the children 
Prior to disclosure, the most common question children asked was why they had to continue taking 
medication, even when they did not feel sick. They also wanted to know when they would stop taking 
the medicines. Where the child was the only infected child in the family, they would ask why their other 
siblings did not have to take medicines all the time. Two children asked if they could share their 
medicines with their other siblings when they were sick.  
  She kept asking why she is taking medicine. When will she stop? 
Why this too much drugs every day like this. He say how long he will take it before 
stopping? 
  Why only me taking these drugs? My younger ones are not taking. 
  Wen my broda sick make I give am? 
One child also asked why he was not allowed to go to boarding school, since it was common in Nigeria 
for children in secondary schools to live in boarding schools. 
Why no boarding school? Every sibling has gone to boarding school. Now he knows why. 
 
After disclosure, seven parents reported that their children had stopped asking any questions about 
their health, or the reason for continuing to take drugs. One child also asked how he became infected, 
and wondered if his parents were also infected. Two children still continued to ask when they will stop 
taking their drugs. 
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She has not asked any questions since then. She is content with the answer I gave her. 
  He always ask about how come [he got infected]? Are his parents infected? 
Child’s refusal to accept a positive HIV-diagnosis 
There was a case of an 11-year old boy who was told by his 60 year old aunt, who was also his caregiver, 
that he was living with HIV. But he refused to accept his status. It seemed so improbable to him that he 
would be infected with HIV.  
  E dey ask from where HIV come wey em catch am. 
Challenges parents face with disclosure 
Most parents described the difficulties and stress they felt with disclosure – either not feeling they had 
the right skills to disclose, or they worried about how the child would feel and react to the news of their 
HIV-positive status.  
I didn’t tell her then because I found it difficult. How would she feel? But that night I 
told her. Even me myself I was relieved. I did not find it easy. I found it difficult to tell 
her. If she had been taking her medicine I would not have told her.  
Some parents broke down in tears as they shared their experiences and concerns about their children, 
and their future, and how they would cope with living with HIV. 
I just had to tell him. I feel he can’t be taking drugs without knowing. Though I found it 
so difficult to tell him, I as a father, I don’t have it.  Even the mother and the other 
children. He is the only one.  [Father broke down when narrating the experience] 
One parent, however, felt his vocation as a preacher prepared him to disclose to his child. 
I was prepared through religion- preaching every morning, prayers. 
Parents’ concerns for their children 
While much needed attention is now being focused on how children experience living with HIV, it is 
important to remember that parents also find caring for CLHIV distressful. At the end of the interviews, 
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the PI invited parents to ask any questions. Most parents appreciated the opportunity to talk with 
somebody, not just about medicines and medical issues, but the struggles they were having with HIV as 
an illness in the family. Parents’ concerns went beyond medical issues, to other challenges with life, in 
general. Some of these concerns become more poignant when cast in the context of HIV. Such fears 
included concern for the other siblings being inadvertently infected with HIV by the CLHIV. One father of 
two girls sent the younger, non-infected child, to live with the child’s grandmother. He was concerned 
that the older girl, who was living with HIV, could infect the younger one. He felt since they were both 
young children, they may not be careful while playing with sharp objects, and may inadvertently infect 
the younger child.  
The major concern another mother had was about her two teenage girls getting married. 
According to her, the church they attended would not allow the children to be married in church, even 
to another person who was HIV-positive. Their church would not wed them. A widower and father of 
four children, who had already lost two children to AIDS, and the surviving two boys were living with the 
virus was concerned with how he would keep the surviving children alive. He was very grateful for the 
free treatment program at the clinic, and the work by health workers to keep patients alive. He had 
been tested and found negative, but his late wife was positive.  
The role of schools in HIV disclosure 
No parent reported disclosure happening in schools, or about teachers or other school personnel being 
involved in disclosure. However, some parents mentioned that the lessons provided in schools on HIV 
helped them disclose to their children. Many respondents mentioned that knowing their children were 
already learning about HIV helped them to disclose. They felt it was easier to disclose because the 
children had some knowledge about HIV.  
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The main concern parents mentioned in relation to schools, was how to deflect the children’s 
questions about not going to boarding school. It is common practice in Nigeria for children to live in 
boarding schools while attending secondary school (from 9 - 10 years or above). Due to concerns about 
disclosure of status, and medication adherence, many parents of CLHIV chose for their children to 
attend secondary school from home. However, these children felt they were missing an important 
experience compared to their mates. 
He’s the last [child]. Why no boarding school? Every sibling has gone to boarding school. 
I told him a lie. I told him he was my last child, so I wanted him around me. He accepted 
it. Now he knows why.  
 
DISCUSSION 
The findings from this study are consistent with those reported in similar qualitative studies in SSA. 
Children are often disclosed because of repeated questioning from the children [4] [5] [13], and the 
parents’ perception that children are cognitively mature to understand their diagnosis [4] [7]. As has 
been reported in other studies, this study showed that fear of inadvertent disclosure and child’s young 
age are main barriers to disclosure [4] [5] [7] [8] [13]. Similarly, this study also showed that the 
disclosure process is often a one-off event that is often unplanned [12], even though WHO guidance on 
pediatric disclosure encourages that disclosure should involve a series of discussions.  
Children’s reactions to disclosure in this study were similar to those reported by other studies. 
They included no reaction, to shock, and crying. Many parents in this study attributed their children’s 
lack of reaction to the children’s young age and lack of understanding of the news. This has been 
observed in other studies [12].  However, some of these studies that also included interviews with the 
children, showed the children had a different experience of the disclosure process/news than their 
parents. They were quiet, not because they were too young and did not understand the news, but chose 
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not to ask questions or react to the news, despite the questions and concerns they had about the news 
of their diagnosis [12].  
Although this study showed that both parents and health care workers disclosed to children, it 
was outside the scope of this study to determine which was better, and therefore, who should disclose – 
parents or health care workers, or where disclosure should take place – the hospital or home, or which 
had more benefits.  The study also did not systematically seek information on parents/caregivers’ own 
HIV status and how that affected or did not affect disclosure, although some parents/caregivers 
volunteered information on their HIV status (positive or negative) in the course of the discussions. 
This study suggests that schools already play an important role in disclosure by providing basic 
HIV education to children, as part of the school curriculum. Schools could also play an even bigger role 
by providing an additional and alternative environment for disclosure. Some parents reported their 
concerns around their children being able to go to boarding school, like other children, due to concerns 
with medication adherence and disclosure. Most children in Nigeria go on to live in boarding schools 
when in secondary school from age 9 to 12 years. As WHO notes in its pediatric disclosure guidance 
document, this and many other school-related issues for children suggest that this is an important area 
for study [2]. School personnel could prove to be other “safe” persons outside the family who could 
assist with pediatric disclosure [2]. 
Health care workers already play an important role in pediatric disclosure by encouraging 
parents to disclose to their children, and also helping to disclose when necessary. Some parents 
mentioned they would not have disclosed if they had not been asked by health care workers to disclose 
to their children. But some parents still report their lack of skills to disclose, despite their desire to 
disclose. Health care workers could, therefore, facilitate more disclosure by building parents’ skills to 
disclose. The PI’s conversations with health care workers at UATH did not show that this was happening 
systematically or in a structured way.  
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This study noted two cases of inadvertent disclosure. It is not clear how this compares with 
children who were intentionally disclosed. In any case, parents and health care workers need to ensure 
such inadvertent disclosure is prevented. 
One child refused to accept his HIV diagnosis, asking where HIV “came from” that he could have 
been infected. This could be an indication of the quality of the disclosure process, and the inadequacy of 
the information provided to the child by his parent/caregiver during disclosure.  This 11-year old boy, 
who was disclosed to by his 60 year old aunt (caregiver), was perinatally infected. This example makes a 
case for ensuring that the disclosure process is structured in terms of how it happens and that adequate 
information is provided during the process. A disclosure guidance could, therefore, be a helpful 
document for parents and health care workers on how to disclose to children living with HIV. 
Stigma and discrimination remain an important barrier to pediatric disclosure [7] [13]. Some 
parents explained their concerns about being seen at the paediatric clinic – especially by health care 
workers from other departments who they knew, since being seen at the clinic would indicate that their 
child was HIV positive. One female respondent mentioned how she always prayed on each clinic day 
that nobody they knew would see them in the clinic. This study highlights how such concerns also 
contributed to non-disclosure of status to children, as parents want to wait until children are older and 
would not divulge information about their status. 
Religion plays an important role in life in Nigeria. It was therefore, surprising that religious 
leaders were not playing a more visible role in disclosure. One parent described how her pastor stepped 
in when she was experiencing stigma and discrimination from other church members. Due to the 
pastor’s intervention, the discrimination stopped. However, the church and mosque could play a more 
active role in disclosure. More studies are needed to describe if, and how, religious leaders are involved 
in disclosure, and in addressing stigma and discrimination. They are already actively involved in the 
larger HIV response, and could be effective agents in disclosure. 
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Most respondents were themselves HIV-positive, and many would come to the clinic both for 
their own clinic consultations with the doctor at the adjoining adult ART clinic, and for their child’s. Due 
to the very high patient volume and long queues at the adult ART clinic many kept shuttling between the 
adult clinic and the pediatric clinic. As such, they could not spare too much time for the interview and 
questionnaire. This, therefore, limited the amount and scope of probing that the PI could undertake. 
Visiting parents in their homes was not a viable option due to concerns about stigma and the related 
cost of this option. Neither, was scheduling another time for parents to return to the clinic for the 
interview an option, due to the cost implications – for parents and the PI. No respondent agreed to be 
audio-taped. The PI, therefore, had to rely on taking as much notes by hand as possible. This limited the 
amount of information that could be gathered. 
CONCLUSIONS  
By far the most common reason parents/caregivers gave for disclosure was related to the children 
taking their drugs. The disclosure process suggest that this was usually a discrete, one-off event that was 
unplanned. Children’s immediate reaction ranged from no reaction, to sadness, ange and crying. Some 
parents described their difficulties with disclosure, including not feeling they had the right skills to 
disclose. Health care workers could therefore facilitate more disclosure by building parents’ skills to 
disclose. Religious leaders could be more actively involved in disclosure, and the reduction of stigma and 
discrimination against persons living with HIV. Schools could also provide an additional environment for 
disclosure. 
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CHAPTER 6 
PLAN FOR CHANGE 
INTRODUCTION 
Key findings from this study include a low pediatric HIV disclosure rate at 30.9%, with 10.19 years as the 
mean age at disclosure, and three (30%) of the 10 children in the study aged ≥ 15 years not knowing 
they are HIV positive. The study also showed that most children (79.4%) were disclosed to at home by 
their parents/caregivers. The process of disclosure was not usually planned – neither by health care 
workers nor parents. Some parents/caregivers expressed they lacked the skills to disclose to their 
children. Health care workers at UATH – the study site - did not have any detailed guidance or manual 
on how to work systematically with CLHIV and their parents/caregivers to ensure disclosure. While the 
study did not interview children directly, some parents/caregivers reported that their children were 
affected emotionally, albeit in the short term, by learning their HIV status. 
These findings stand in stark contrast to the World Health Organisation guideline on pediatric 
disclosure. WHO published the Guideline on HIV disclosure counselling for children up to 12 years of age 
in 2011 [1]. The guideline provides definitive and evidence based guidance to health care workers and 
pediatric HIV program managers on when, who and how to inform children of their own and caregivers’ 
HIV status. The following are some of the key WHO recommendations on pediatric HIV disclosure: 
1. Children of school age (6 – 12 years) should be told their HIV positive status. Younger children 
should be told their status incrementally to accommodate their cognitive skills and emotional 
maturity, in preparation for full disclosure. 
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2. The decision on who will disclose to the child should be guided by the intent to improve/ promote 
the child’s welfare and minimize the risk to his or her well-being and to the quality of the 
relationship between child and parent/caregiver. 
3. Initiatives should be put in place to enforce privacy protection and institute policy, laws and norms 
that prevent discrimination and promote tolerance and acceptance of people living with HIV. This 
can help create environments where disclosure of HIV status is easier. 
Even though this guideline has been in the public domain for four years now, as far as is known, 
no country in SSA, including Nigeria, has developed its own detailed national pediatric HIV disclosure 
guidelines. The Nigeria Integrated National Guidelines for HIV Prevention, Treatment and Care includes 
half a page of information on the importance of HIV disclosure to children [2]. It proposes the following 
steps for pediatric HIV disclosure: 
 Evaluate the child and family for readiness-including child’s age and maturity. Five to seven years 
are earliest recommended ages for disclosure, and all [children] should be disclosed by age 12 
years.  
 Ascertain a child’s and caregiver’s understanding of HIV infection  
 Explain the benefits of early awareness of HIV infection to the child and care giver/family  
 Provide ongoing psychosocial support.  
This, however, is a far cry from the guidance that health care workers require – as findings from this 
study show - to be able to appropriately and effectively counsel and guide CLHIV and their 
parents/caregivers on disclosure. 
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STUDY RECOMMENDATION 
The one recommendation from this study is, therefore, for the Government of Nigeria to develop 
national standard operating procedures or protocols and a training manual for health care 
workers and parents/caregivers of children living with HIV that will promote child HIV disclosure 
in order to address the current low rate of disclosure in the country. 
One objective of this study is for its findings to add to the existing body of scientific knowledge 
in the field of care and treatment for children living with HIV, and further the understanding of the 
factors that facilitate and hinder HIV disclosure to children in resource limited settings. It is expected 
that this body of knowledge will be useful in developing guidelines for HIV disclosure to children – in 
Nigeria and elsewhere on the continent.  
Study findings will also be useful in designing HIV related guidelines in the education setting. As 
more CLHIV reach school age, such guidelines also need to include disclosure to education personnel in 
the school environment, and how to build capacity in the school environment to limit stigma and 
facilitate support for CLHIV in schools. Although the decision to inform schools of the child’s HIV status 
should remain a family decision, providers and program managers can facilitate the process and help 
build family capacity to do this. 
MOVING FROM RESEARCH TO POLICY AND GUIDELINES: THE ADVOCACY PLANNING FRAMEWORK 
This chapter presents an implementation plan for how the findings from this study will be used to 
advocate for the development of standard operating procedures or protocols (SOPs) and a training 
manual for pediatric HIV disclosure in Nigeria, using an adaptation of the Advocacy Planning Framework 
(APF) [3] . First, is the presentation of the strategic focus and the three pillars of the APF, followed by 
how the APF will be applied in advocacy efforts to move the policy development process for pediatric 
HIV disclosure in Nigeria. 
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According to Young and Quinn [3] policy advocacy focuses on influencing decisions of public 
policy. They define “successful advocacy as a process through which the main target audiences, 
including decision makers, need to build ownership of the ideas and proposals put forward, which will 
then direct them in leading any upcoming decision” (page 56). The APF is a simple tool for advocacy that 
consists of a core strategic focus and three pillars (Figure 6.1). These three pillars are: (1) Way into the 
Process – which seeks to determine the best approach to get one’s issue into the policy debate, and 
who should be the target audience(s) for advocacy; (2) The messenger – which seeks to determine who 
should lead or be the face of the advocacy efforts; and (3) The message and activities – which seeks to 
determine the messages and activities that will be effective in reaching the target audience(s). Three  
Figure 6.1 The Advocacy Planning Framework
 
Adapted from Young & Quinn (2012) 
strategic questions that will help to build these three pillars are: (1) Map out the current obstacles and 
challenges to the policy initiative. That is, the barriers that are blocking the policy making process from 
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moving forward; (2) Assess what leverage one can bring to the advocacy process; and (3) Set a feasible 
advocacy objective or endpoint for the advocacy initiative. This should focus on the change one seeks to 
see, and how far one thinks the advocacy process can be moved forward, and not necessarily on the 
policy outcome. 
ADVOCACY PLANNING FOR THE DEVELOPMENT OF PEDIATRIC HIV DISCLOSURE GUIDELINES 
A. Strategic focus for advocacy 
Mapping the current obstacles and challenges: It is not envisaged that there will be substantial 
opposition to developing SOPs or a training manual for pediatric HIV disclosure. The main challenge will 
be to gather enough momentum from civil society organization (CSO) stakeholders to trigger the 
process, amidst the competing program and funding priorities in these organizations. The usual practice 
for developing national tools, is for a CSO or coalition of CSOs to spearhead the process, by developing 
draft protocols and training manuals for use in their own programs. It is then often easier to follow up 
with adopting or adapting these documents for national use, thereafter. Recent discussions indicate that 
at least one CSO is already developing pediatric disclosure related documents. The PI will work closely 
with this CSO and government focal persons in the two key government ministry and agency – the 
National Agency for the Control of AIDS (NACA), and the National AIDS/STIS Control Programme (NASCP) 
- as well as UNICEF to move this issue into the national discourse.  
 A key opportunity for the advocacy process is the publication of the WHO guideline [1]: What 
Young and Quinn [3] term the “policy spillover,” or an international trend that can catalyse policy 
discussion in many countries. PEPFAR also requires disclosure as an element of the package of care 
provided to CLHIV by PEPFAR supported programs. These two opportunities already “soften up” the 
process for advocating for the development of Nigeria-specific guidance documents [3, page 125]. 
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Assessing leverage for advocacy: This study is one of few studies on pediatric disclosure in Nigeria. To 
date, there is only one published peer-reviewed work on pediatric HIV disclosure on Nigeria [4]. 
Therefore, the findings from this study will be welcome. The PI has also worked in the adolescent and 
reproductive health arena for over a decade. The stakeholder network that has been developed in-
country in these fields and familiarity with key government and civil society stakeholders will help in 
advocating for the proposed change/development in the country.  
Setting a feasible objective for advocacy: The objective of this advocacy effort will be to move forward 
the process of developing national SOP, and training manuals for health care workers and 
parents/caregivers on pediatric HIV disclosure. The country recently moved towards the consolidation of 
HIV guidelines. Instead of having separate guidelines for HIV prevention, treatment and care, the 
separate existing documents were consolidated into one document in 2014 [2]. Therefore, advocating 
for a separate pediatric HIV disclosure guideline will likely meet with stiff opposition from many 
stakeholders. However, it is clear that SOP, and training manuals are needed by stakeholders, especially 
program managers and health care workers, as these documents will facilitate the practical 
implementation of the recommendations in the consolidated guidelines. One sub-objective of this 
advocacy initiative will, therefore, be to get the discussion of the development of the SOP and training 
manuals on the agenda for the next pediatric HIV technical working group (TWG) meeting. The TWG is 
where most program managers and health care workers meet regularly to discuss technical issues.  
B. Detailed mapping and planning process 
Way into the process: The main aim of this APF pillar is a detailed mapping of the policy landscape in 
order to understand the key policy actors and their influence. Key information from this stakeholder 
analysis will include mapping the key policy decision makers that should be influenced; clarifying the 
position of these key actors in relation to the proposed advocacy intervention; understanding the policy 
or guideline making process; and identifying the opportunities and best timing for this advocacy effort. 
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The main strategy for this stakeholder mapping will be one-on-one meetings with pediatric HIV focal 
persons at government ministries and agencies, such as the Federal Ministry of Health, NACA, CSOs and 
UNICEF. 
The messenger: This will be the key stakeholder who will lead the advocacy efforts, and be the 
champion and “face” for this advocacy. Young and Quinn suggest identifying such a champion from 
within or close to the government sector [3].  However, considering that the process of developing 
guidelines, SOPs and training manuals is often initiated by program implementing partners that need 
such guidance documents for their program implementation, the PI may choose a champion from an 
implementing partner or a multilateral organisation, such as UNICEF. In view of the very hierarchical 
structure of the government sector, a champion from within the government sector would need to be 
high up the ladder to be influential. Incidentally, the program focal persons are often lower cadre 
officers in the ministry, who will not be able to rock the boat.  
 Implementing partners and UNICEF have the financial resources to fund national meetings and 
workshops for developing, adapting and adopting national guidance documents. This is an important 
consideration, as the lack of funds can sometimes hinder the policy development process. Such a 
champion will have to be credible, and reputable among stakeholders. Beyond identifying a champion 
for the advocacy efforts, it will be helpful to identify other supporters of this effort from among the 
identified stakeholders and build a coalition of support around this issue. 
Activities: Key advocacy activities will include one-on-one meetings with key stakeholders, such as focal 
persons at key government ministries and agencies, UNICEF and program implementing partners. The PI 
will focus on two implementing partners – IHVN and FHI 360 – that are key players in the pediatric HIV 
arena. Other activities will include participating in technical working group meetings, and presentations 
at conferences – local and international, and at TWG meetings.  Publication of study findings in peer 
reviewed journals will also enhance the value of the study findings for advocating for the development 
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of the guidance documents. Table 6.1 summarizes the key activities for advocating for the development 
of national pediatric HIV disclosure SOP and training manuals. 
Table 6.1 Key activities for advocating for the development of pediatric HIV disclosure guidance 
S/N Key Activities Objectives/Comments Timeline 
1 Finalise and submit three manuscripts on the 
study findings to peer reviewed journals 
This will increase the advocacy 
value of the study findings 
Nov 2015 
2 Map the actors, network, and power centers: 
- Who they are 
- What is their current thinking and 
position on pediatric HIV disclosure 
guidance 
The focus will be on these actors: 
- NASCP, NACA (Government) 
- UNICEF (multilateral) 
- IHVN, FHI 360 (CSO/IPs) 
- Others 
Nov 2015 
3 Clarify the process for the development of 
national standard operating procedures and 
training manuals 
The aim will be to determine the 
current opportunities and how to 
align advocacy efforts through 
TWG and other national level 
meetings and events 
Nov 2015 
4 Choose the face of the advocacy efforts The aim is to identify which 
stakeholder is best positioned to 
lead the broader advocacy/ 
guidance development process 
Nov - Dec 
2015 
5 Mobilize other support Identify and mobilize other 
supporters of pediatric HIV 
disclosure 
Nov - Dec 
2015 
6 Select and implement advocacy activities and 
communication tools and channels 
Mostly publication and other 
literature 
Oct 2015 – 
Mar 2016 
7 Plan for challenges and responses This will be ongoing – developing 
responses as challenges emerge 
Oct 2015 - 
Mar 2015 
Message: Different messages will be tailored to the different audiences, as shown in Table 6.2. 
Suggestions for crafting appropriate messages include providing arguments to the various audience 
segments, “how seen from their perspective, it makes sense to change” [3, page 118].  Also including a 
mix of carrots (incentives) – what they stand to gain from developing the guidance documents;  and 
sticks (sanctions) – what they stand to lose if the guidance documents are not developed, are useful 
hints for effective messages [3, page 118]. 
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Table 6.2 Tailored messages for advocacy audiences 
Audience Message 
Government 
 There are already Nigeria-based studies - including this one – 
that show very low rates of disclosure, and the desire by 
parents/caregivers to learn skills on how to disclose. In other 
words, there is a “consumer” need for the guidance.  
 Nigeria will be seen internationally as being a frontrunner to 
develop national pediatric HIV guidance documents (“carrot”) 
 WHO has published the pediatric HIV guideline that will be useful 
in the Nigeria process 
UNICEF 
 WHO has published disclosure guideline that could be useful 
 UNICEF will be seen as promoting conformity with WHO (a sister 
body) recommendation (“carrot”) 
Implementing partners 
(CSO) 
 As PEPFAR partners, implementing partners are already required 
to develop disclosure guidance and provide disclosure services, 
as part of the package of care for HIV-infected children (“carrot”) 
 Many infected adolescents may be starting sexual activity, and if 
not disclosed may infect others (“stick”). 
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APPENDIX 1: QUESTIONNAIRE FOR PARENTS/CAREGIVERS OF PEDIATRIC ART PATIENTS 
(Complete the following)   
1. Date of interview________________________________ 
 
2. Location______________________________ 
 
3. Respondent – Male/Female----------------------------------- 
 
4. Child – Male/Female----------------------------------- 
 
5. Interviewer---------------------------------------------------------------- 
 
6. Language of interview---------------------------------------------------- 
 
7. Questionnaire Ref. No____________________________ 
 
Introduction and Consent My name is Angela Odiachi. I am a University student conducting research on 
health. This study has been reviewed and granted permission by both my 
University Research Ethics Committee, and the University of Abuja Teaching 
Hospital Ethics Committee. I would very much appreciate your participation 
in this study. This information will help both governments and program 
managers to plan health services. The survey usually takes between 20   and 
25 minutes to complete. Whatever information you provide will be kept 
strictly confidential and will not be shown to other persons. Should you have 
any questions, please feel free to call any of the following contact person(s): 
UATH Contact Person: (designation)---------------; Email:------------- Phone:  
UNC Contact Person: (designation)--------- Email: --------------- Phone: --------- 
All of the answers you give will be confidential. Participation in the survey is 
completely voluntary. If I should come to any question you do not want to 
answer, just let me know and I will go on to the next question; or you can 
stop the interview at any time. However, I hope you will participate in the 
survey since your views are important. 
At this time, do you want to ask me anything about the survey? 
May I begin the interview now? 
A: Ice breaker 1. Can you tell me why you came to the hospital today? 
 
 
2. What year did child start receiving treatment at this health  
facility? -----Year ------------------  
B: Disclosure I am  now going to ask you some questions about child’s health 
3. What year did child start taking ART medicine? 
Year _________ 
Month___________ 
Don’t know________________ 
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4. What year was child diagnosed with HIV? 
Year _________ 
Month___________ 
Don’t know________________ 
 
 
5. Does child know s/he has HIV? 
 
(1) Yes 
(2) No 
(8) Don’t know 
 
6. Does child know s/he comes to clinic for HIV care? 
 
(1) Yes 
(2) No 
(8) Don’t know 
 
7. Does child know that the name of his/her sickness is HIV? 
 
(1 ) Yes 
(2) No 
(8) Don’t know 
 
8. Does child know that s/he is taking medicine for HIV? 
 
 (1 ) Yes 
( 2) No 
(8 ) Don’t know 
 
If No to Question 5 to 8, skip to Q 14 
C: Disclosure Context 
- When diagnosed 
- Setting 
- By whom 
 
I am  now going to ask you some questions about child’s health 
 
9. Who informed child that s/he had HIV? 
 
( 1 ) Parent/caregiver 
( 2 ) Health care provider 
( 3 ) Pastor/Imam/Clergy 
( 4 ) School personnel 
( 4 ) Child was told by a relative  
(5  ) Child was told by _______--(someone else, please specify) 
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( 6  ) Child saw his/her health report  
( 7 ) Other method ___________(specify) 
( 8) I don’t know 
 
10. Where was child told he had HIV? 
 
(1) At home 
(2) At the hospital 
(3) At  school  
(4) At church  
(5) Other, specify________________ 
(8) Don’t know 
 
11. Why was child told s/he had HIV? 
 
(1) To help him/her take his/her medicines regularly/ Child 
refused to take medicines 
(2) To improve their health 
(3) Child is now mature/old enough 
(4) Child was asking a lot of questions about his/her 
illness/medicines 
(5) Child was about to start school 
(6) Child refused to come to hospital 
(7) So they do not infect others 
(8) Child may become sexually active 
(9) So child can protect him/herself 
(10) Other, specify_______________ 
(88) Don’t know 
 
12. What year did child learn that s/he had HIV? 
Year___________ 
Month_______________ 
 
13. How old was child when s/he was told s/he had HIV? 
__________________________ years 
 
 (8  ) Don’t know 
D: Non-disclosure 
 
14. Why have you not told child s/he has HIV?  
 
(1  ) It will make them sad 
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( 2 ) It will make them angry 
( 3 ) they will not be able to keep it a secret 
(4  ) Child is too young 
(5  ) Child will blame parent  
(6) Child will refuse to take his/her medicines 
(7) Child will refuse to come to clinic 
(8) Do not know how to disclose to child his/her status 
(9) Other people may find out 
(10)The child may be afraid they might die and give up 
(11 ) Other, specify___________________________________ 
(88) Don’t know 
 
 
15. Do you have any suggestions on what will help you disclose 
child’s status to him/her? 
 
---------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------
-------------- 
E: Sociodemographics 
 
I am now going to ask you some questions about child and his/her family 
16. In what month and year was child born? 
 
Year _________________ (9998) Don’t know Year 
Month_________________(98)___Don’t know month 
 
17. How old was child at last birthday? 
---------------------------- (AGE IN COMPLETED YEARS) 
 
COMPARE AND CORRECT Q.16  AND/OR Q.17 IF INCONSISTENT 
 
 
18. Is child in school? 
 
(1 ) Yes 
(2 ) No 
( 8) Don’t know 
 
IF NO, SKIP TO Q 20 
 
19. During this school year, what level of school is child attending? 
(1 ) Kindergarten 
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(2) Primary 
( 3) secondary 
( 4) Post-secondary/Higher 
(5 ) Other, specify_______________________ 
 ( 8) Don’t know 
 
20. What is child’s tribe? 
(1 ) Hausa 
(2 ) Igbo 
(3 ) Yoruba 
( 4) Other, specify------------------------------------- 
( 8) Don’t know 
 
21. How are you related to the child? 
(1 ) Mother 
( 2) Father  
( 3) Sibling  
( 4) Uncle 
( 5) Aunt 
( 6) Grandparent 
(7) Other, specify_____________________________ 
( 8) Don’t know 
 
22. Are you child’s caregiver? 
(1 ) Yes 
(2 ) No 
( 8) Don’t know 
 
23. How old were you at your last birthday? 
 
-----------------------------AGE IN COMPLETED YEARS 
 
24. Have you ever attended school?  
(1 ) Yes 
(2 ) No 
( 8) Don’t know  
 
25. What is the highest level of school you attended:  
(1) Primary 
( 2) secondary 
( 3) Post-secondary/Higher 
(4 ) Other, specify_______________________ 
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( 8) Don’t know 
 
26. What is your religion? 
(1) Christian 
(2) Muslim/Islam 
(3) Traditionalist 
(4) Others, specify________________ 
 
27. What is your tribe? 
 
(1) Hausa 
(2) Igbo 
(3) Yoruba 
(4) Others, specify------------------------------------ 
Conclusion I have come to the end of my questions. Do you have any questions for me? 
Thank you for your time. 
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APPENDIX 2: PATIENT DATA EXTRACTION FORM 
 
  
10
7 
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APPENDIX 3: INTERVIEW GUIDE FOR PARENTS/CAREGIVERS OF DISCLOSED CHILDREN 
INTRODUCTION: I know you have answered some of the questions I am about to ask you. But I want 
you to feel free to discuss some of the questions in more detail.  
You have mentioned that child was disclosed when s/he was ---- years, and it was ----- who disclosed 
to him/her. 
 
1. (HOW) Can you describe how child found out s/he was HIV positive? 
(Probe for where, when, disclosed by whom?) 
 
 
 
2. (WHY) Can you explain more why was child told s/he had HIV? 
(Probe: what helped you or your family/or made it easier to disclose to child?) 
 
 
 
 
 
 
3. (WHO) You mentioned that child was told by ……Why was it this particular person (and 
not someone else)?  
 
 
 
4. (WHEN) You mentioned that child was -----old when she was told. Can you explain why it 
was this particular age – not earlier or later? 
 
 
 
5. (HOW MUCH) How much do you think child knows about her sickness? Do you think 
child knows s/he has HIV? 
(Probe: Has the word HIV or AIDS or local equivalent been used by anyone in any 
conversation with child about their sickness? If local equivalent term was used, which 
specific term?) 
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6. (VISUAL) If you were to show on a scale like the one below, the bottom mark being the 
child does not know at all, and the top mark being child knows she has HIV, where would 
you place how much child knows on the scale? 
 
    Highest (child knows s/he has HIV) 
 
 
 
 
 
 
 
 
   Lowest (child does not know s/he has HIV) 
 
7. Can you explain why you have chosen this point? 
 
 
 
8. Can you describe some conversations you have had with child about his/her health.  
(Probe: What questions has child asked about his/her health? Who child asked; when; 
where?) 
 
 
 
9. What answers was s/he given? 
 
 
Thank you for your time. I appreciate your participation in the study 
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APPENDIX 4: UNIVERSITY OF ABUJA TEACHING HOSPITAL INSTITUTIONAL REVIEW BOARD LETTER 
OF APPROVAL 
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APPENDIX 5: UNIVERSITY OF NORTH CAROLINA INSTITUTIONAL REVIEW BOARD APPROVAL LETTER 
To: Angela Odiachi 
Health Policy and Management 
 
From: Non-Biomedical IRB 
 
Approval Date: 2/04/2015 
Expiration Date of Approval: 1/12/2016 
RE: Notice of IRB Approval by Full Board Review 
Submission Type: Initial 
Study #: 11-2033 
 
Study Title: The Impact of Disclosure on Health Outcomes in HIV-Infected Nigerian 
Children 
 
This submission has been approved by the IRB for the period indicated.  
 
Study Description:  
 
Purpose: This study aims to explore the association between pediatric disclosure (defined as 
disclosure of child’s seropositive HIV status to the child or informing the child that s/he has 
HIV) and health outcomes in a cohort of HIV-infected children in Nigeria.  The study will: 
(1) Determine the rate and nature of HIV status disclosure, and identify the main agent of 
disclosure; (2) Determine age at HIV disclosure (3) Investigate locally pertinent barriers to, 
and facilitators of disclosure and (4) Investigate associations between disclosure, and health 
outcomes (adherence, viral load, CD4, and Opportunistic infections). 
 
Participants: These will be 140 parents/caregivers of children living with HIV at the 
Pediatric ART clinic, of the University of Abuja Teaching Hospital, Abuja, Nigeria 
 
Procedures (methods): The study is in two parts: (1) Quantitative component that explores the 
association between pediatric disclosure and health outcomes. This will involve 
administering a questionnaire to 140 parents/caregivers of paediatric ART patients; and also 
extracting health data on the children from their medical records (2) Qualitative component 
that consists of indepth interviews with a minimum of 10 parents/caregivers of disclosed 
children to determine the context and process od disclosure to children.  
 
Regulatory and other findings: 
 
This research, which involves children, meets criteria at 45 CFR 46.404 and/or 21 CFR 50.51 
(research involving no greater than minimal risk). Permission of one parent or guardian is 
sufficient.  
The IRB has determined that assent of the children may be waived according to 45 CFR 
46.408(a) and/or 21 CFR 50.55(c)(1). The capability of some or all of the children (based on 
age, maturity or psychological state) is so limited they cannot reasonably be consulted about 
their willingness to participate. For the children six and below. 
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The IRB has determined that assent of the children may be waived according to 45 CFR 
46.408(a) and/or 21 CFR 50.55(c)(2) because the intervention or procedure(s) involved, 
available only in the context of the research, offers a prospect of direct benefit that is 
important to the health or well-being of the children. 
  
 
Investigator’s Responsibilities:  
 
Federal regulations require that all research be reviewed at least annually. It is the Principal 
Investigator’s responsibility to submit for renewal and obtain approval before the expiration 
date. You may not continue any research activity beyond the expiration date without IRB 
approval. Failure to receive approval for continuation before the expiration date will result in 
automatic termination of the approval for this study on the expiration date. 
 
Your approved consent forms and other documents are available online at 
http://apps.research.unc.edu/irb/irb_event.cfm?actn=info&irbid=11-2033. 
 
You are required to obtain IRB approval for any changes to any aspect of this study before 
they can be implemented. Any unanticipated problem involving risks to subjects or others 
(including adverse events reportable under UNC-Chapel Hill policy) should be reported to 
the IRB using the web portal at http://irbis.unc.edu.  
 
Please be aware that approval may still be required from other relevant authorities or 
"gatekeepers" (e.g., school principals, facility directors, custodians of records). 
 
The current data security level determination is Level III. Any changes in the data security 
level need to be discussed with the relevant IT official. If data security level II and III, 
consult with your IT official to develop a data security plan. Data security is ultimately the 
responsibility of the Principal Investigator. 
 
This study was reviewed in accordance with federal regulations governing human subjects 
research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 (HIPAA), 21 
CFR 50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable. 
 
CC: 
Harsha Thirumurthy, Health Policy and Management IRB Informational Message - please do 
not use email REPLY to this address 
 
 
 
